Enzymatic compositions for carbohydrate antigen cleavage, methods, uses, apparatuses and systems associated therewith

A combination of GalNAc deacetylase and galactosaminidase enzymes efficiently converts A antigens to O type in red blood cells, addressing inefficiencies in existing methods by reducing enzyme requirements and maintaining cell viability, suitable for blood collection and storage.

JP2024163994AActive Publication Date: 2024-11-26THE UNIV OF BRITISH COLUMBIA
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
JP2024111653
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-08-17
Filing Date
2024-07-11
Publication Date
2024-11-26
Estimated Expiration
2039-08-16

AI Technical Summary

Technical Problem

Existing methods for converting blood type A or B red blood cells to type O are inefficient and require significant amounts of enzyme, making them impractical for widespread use in transfusion medicine, particularly for type A conversion due to the complexity of A blood subtypes.

Method used

A combination of GalNAc deacetylase and galactosaminidase enzymes, optimized for efficiency and pH stability, is used to cleave A antigens from red blood cells, with the addition of crowding agents enhancing enzyme activity, allowing for conversion at low enzyme concentrations.

Benefits of technology

The enzyme combination efficiently converts A antigens to O type at low enzyme doses, maintaining red blood cell viability and enabling practical large-scale conversion of blood types, suitable for blood collection and storage protocols.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163994000013
    Figure 2024163994000013
  • Figure 2024163994000014
    Figure 2024163994000014
  • Figure 2024163994000015
    Figure 2024163994000015
Patent Text Reader

Abstract

To provide an enzyme capable of more efficiently cleaving a carbohydrate antigen from cells.SOLUTION: The present invention provides an isolated nucleic acid sequence, encoding (a) a GalNAc deacetylase with a specific sequence or (b) Galactosaminidase with a specific sequence, and a vector comprising the nucleic acid sequence and a heterologous nucleic acid sequence. The vector may also include a heterologous nucleic acid sequence, selected from one or more of protein tags and cleavage sites.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] (CROSS-REFERENCE TO RELATED APPLICATIONS) This application claims the benefit of U.S. Provisional Patent Application No. 62 / 719,272, filed August 17, 2018, entitled "Enzyme Compositions for Carbohydrate Antigen Cleavage, Related Methods, Uses, Apparatuses and Systems."

[0002] The present invention relates to the field of enzyme compositions. In particular, the present invention relates to providing enzyme compositions for cleaving antigens, as well as uses, methods, devices and systems for cleaving antigens using said compositions. [Background technology]

[0003] Accurate matching of blood types is a central requirement in transfusion medicine, since the plasma of individuals with blood type A contains antibodies against B antigens, and vice versa, which may result in complement activation and red blood cell (RBC) lysis upon incompatible transfusion (Daniels 2010). These cell surface antigens are carbohydrate structures that terminate with α-1,3-linked N-acetylgalactosamine (GalNAc) or galactose (Gal) for blood types A and B, respectively. On the other hand, type O red blood cells do not contain these terminal sugars and can be transfused universally (Garratty 2008). Therefore, blood banks need to have sufficient supplies of type O red blood cells for emergency situations when the patient's blood type is unknown or unclear. However, supplies are often limited.

[0004] The concept of enzymatic removal of GalNAc or Gal structures from A or B RBCs as a means of converting A or B RBCs to O was first proposed and demonstrated by Goldstein (Goldstein 1982; US4609627 and CA2272925). Using α-galactosidase from green coffee beans, B RBCs were successfully converted to O RBCs followed by transfusion (Kruskall 2000). However, the amount of enzyme required made this approach impractical. Conversion of A blood group is more difficult, mainly because there are many subtypes of A blood group that differ in their internal linkages (Clausen 1989). Similarly, α-galactosidase has been used to remove B antigens (see, for example, EP2243793). Major progress towards practical conversion involving A conversion was made by screening bacterial libraries for both A and B conversion activity using a tetrasaccharide substrate. Two new families of glycosidases that exhibit high antigen cleavage activity at neutral pH values ​​have been discovered (CAZy GH109 α-N-acetylgalactosaminidase and GH110 α-galactosidase (Liu 2007)). Both enzymes completely removed their respective antigens and converted the corresponding RBCs. However, a significant amount of enzyme was required (60 mg enzyme / blood unit), especially for the conversion of type A, limiting further development. Enzymes that more efficiently remove carbohydrate antigens from cells would be useful. Summary of the Invention

[0005] The present invention is based, in part, on the surprising discovery that the combination of galactosaminidase and GalNAc deacetylase, as described herein, is orders of magnitude more efficient than previously identified A antigen cleaving enzymes. For example, under certain conditions, some GalNAc deacetylase and galactosaminidase enzymes may be able to cleave A antigen at 1 μ / ml or less. Furthermore, the cleavage efficiency of the enzyme combination is maintained at a pH suitable for maintaining red blood cell viability (i.e., a pH between about 6.5 and about 7.5). Furthermore, the enzymes are found to be active at temperatures between 4° C. and 37° C., which are also suitable for blood collection, washing and storage protocols. Furthermore, the efficiency of the enzymes is further improved by the addition of crowding agents (e.g., dextran). It is also understood that the same two-step removal process can be applied to donor organs. The enzyme described herein works better on samples with 10% hematocrit and the amount needed for a bag (about 220 ml) packed with red blood cells (RBCs) containing about 80% hematocrit was calculated.

[0006] In some embodiments lacking a crowding agent, a bag packed with 3 μg / ml 10% hemocrit, 1 hour at 37° C., >5.3 mg of each enzyme / rbc may be used to remove A antigen from red blood cells, and in other embodiments with a crowding agent, a bag packed with 0.5 μg / ml 10% hemocrit, 1 hour at 37° C., >0.9 mg of each enzyme / rbc may be used to cleave A antigen from red blood cells. However, it will be understood by those skilled in the art that if the cells are incubated longer, more enzyme can be used to shorten the time the blood can be processed, or less enzyme can be used.

[0007] According to one embodiment, a composition is provided, the composition comprising: (a) a purified GalNAc deacetylase protein; and (b) a purified galactosaminidase protein.

[0008] According to one embodiment, a composition is provided comprising: (a) a purified GalNAc deacetylase protein selected from one or more of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:17, SEQ ID NO:23, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, and SEQ ID NO:35; and (b) a purified galactosaminidase protein selected from one or more of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:36, and SEQ ID NO:37.

[0009] According to a further embodiment, a composition is provided comprising a purified enzyme having GalNAc deacetylase activity consisting essentially of an amino acid sequence at least 90% identical to one of SEQ ID NOs: 2, 4, 5, 17, 23, 29, 31, and 32-35, and a purified enzyme having galactosaminidase activity consisting essentially of an amino acid sequence at least 90% identical to one of SEQ ID NOs: 7, 9, 10, 19, 21, 36, and 37.

[0010] According to a further embodiment, a composition is provided comprising a purified enzyme having GalNAc deacetylase activity consisting essentially of an amino acid sequence at least 85% identical to one of SEQ ID NOs: 2, 4, 5, 17, 23, 29, 31, and 32-35, and a purified enzyme having galactosaminidase activity consisting essentially of an amino acid sequence at least 85% identical to one of SEQ ID NOs: 7, 9, 10, 19, 21, 36, and 37.

[0011] According to a further embodiment, a composition is provided comprising a purified enzyme having GalNAc deacetylase activity consisting essentially of an amino acid sequence at least 80% identical to one of SEQ ID NOs: 2, 4, 5, 17, 23, 29, 31, and 32-35, and a purified enzyme having galactosaminidase activity consisting essentially of an amino acid sequence at least 80% identical to one of SEQ ID NOs: 7, 9, 10, 19, 21, 36, and 37.

[0012] According to a further embodiment, a composition is provided comprising a purified enzyme having GalNAc deacetylase activity consisting essentially of an amino acid sequence at least 75% identical to one of SEQ ID NOs: 2, 4, 5, 17, 23, 29, 31, and 32-35, and a purified enzyme having galactosaminidase activity consisting essentially of an amino acid sequence at least 75% identical to one of SEQ ID NOs: 7, 9, 10, 19, 21, 36, and 37.

[0013] According to a further embodiment, a composition is provided comprising an enzyme selected from one or more of (a) a purified GalNAc deacetylase protein, which is a purified Flavonifractor plautii GalNAc deacetylase protein of SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:5, and (b) a purified galactosaminidase protein, which is a purified Flavonifractor plautii galactosaminidase protein of SEQ ID NO:7, SEQ ID NO:9, and SEQ ID NO:10.

[0014] According to a further embodiment, a composition is provided comprising an enzyme selected from one or more of (a) purified GalNAc deacetylase proteins of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:17, and SEQ ID NO:32, and (b) purified galactosaminidase proteins of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:36, and SEQ ID NO:37.

[0015] According to a further embodiment, a composition is provided comprising an enzyme selected from one or more of (a) a purified GalNAc deacetylase protein, which is a purified Clostridium tertium GalNAc deacetylase protein of SEQ ID NO:17 and SEQ ID NO:32, and (b) a purified galactosaminidase protein, which is a purified Clostridium tertium galactosaminidase protein of SEQ ID NO:19 and SEQ ID NO:36.

[0016] The GalNAc deacetylase and galactosaminidase composition may be capable of cleaving the A antigen at 1 μg / ml or less. The GalNAc deacetylase and galactosaminidase composition may have A antigen cleavage activity at a pH between about 6.5 and about 7.5. The GalNAc deacetylase and galactosaminidase composition may have A antigen cleavage activity at a temperature between 4° C. and 37° C.

[0017] The composition may comprise: (a) the purified GalNAc deacetylase and the purified galactosaminidase may be immobilized; (b) the purified GalNAc deacetylase may be immobilized; or (c) the purified galactosaminidase may be immobilized.

[0018] The immobilized enzyme may be bound to a surface, which may be selected from one or more of the following: (a) a bead or microsphere, (b) a container, (c) a tube, (d) a column, and (e) a matrix. The composition may further include a crowding agent. The crowding agent may be selected from one or more of dextran, dextran sulfate, dextrin, pullulan, poly(ethylene glycol), Ficoll™, and an inert protein.

[0019] According to a further embodiment, a purified enzyme is provided comprising the Flavonifractor proutii GalNAc deacetylase of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:5.

[0020] According to a further embodiment, there is provided a purified enzyme comprising the Flavonifractor platii galactosaminidase of SEQ ID NO:7, SEQ ID NO:9 or SEQ ID NO:10.

[0021] According to a further embodiment, there is provided a purified enzyme comprising the Clostridium tertium GalNAc deacetylase of SEQ ID NO:17 or SEQ ID NO:32.

[0022] According to a further embodiment, there is provided a purified enzyme comprising the Clostridium tertium galactosaminidase of SEQ ID NO:19 or SEQ ID NO:36.

[0023] According to a further embodiment, there is provided an isolated nucleic acid sequence encoding a GalNAc deacetylase selected from one or more of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:16, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28 and SEQ ID NO:30.

[0024] According to a further embodiment, there is provided an isolated nucleic acid sequence encoding a galactosaminidase selected from one or more of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:18 and SEQ ID NO:20.

[0025] According to further embodiments, there is provided a vector comprising the nucleic acid described herein. The vector may also comprise a heterologous nucleic acid sequence, the heterologous nucleic acid sequence being selected from one or more of a protein tag and a cleavage site.

[0026] Protein tags include albumin binding protein (ABP), alkaline phosphatase (AP), AU1 epitope, AU5 epitope, AviTag, bacteriophage T7 epitope (T7-tag), bacteriophage V5 epitope (V5-tag), biotin-carboxy carrier protein (BCCP), bluetongue virus tag (B-tag), single domain camelid antibody (C-tag), calmodulin binding peptide (CBP or calmodulin-tag), chloramphenicol acetyltransferase (CAT), cellulose binding Domain (CBP), chitin-binding domain (CBD), choline-binding domain (CBD), dihydrofolate reductase (DHFR), DogTag, E2 epitope, E-tag, FLAG epitope (FLAG-tag), galactose-binding protein (GBP), green fluorescent protein (GFP), Glu-Glu (EE-tag), glutathione S-transferase (GST), human influenza hemagglutinin (HA), HaloTag™, alternating histidine and glutamine tag (HQ tag), alternating histidine and asparagine tag ( HN-tag), histidine affinity tag (HAT), horseradish peroxidase (HRP), HSV epitope, isopep tag (Isopep-tag), ketosteroid isomerase (KSI), KT3 epitope, LacZ, luciferase, maltose binding protein (MBP), Myc epitope (Myc-tag), NE-tag, NusA, PDZ domain, PDZ ligand, polyarginine (Arg-tag), polyaspartic acid (Asp-tag), polycysteine ​​(Cys-tag), polyglutamic acid (Glu-tag), poly Richtidine (His-Tag), Polyphenylalanine (Phe-Tag), Profinity eXact, Protein C, Rho1D4 Tag, S1-Tag, S-Tag, Softtag 1, Softtag 3, Snoop Tag Jr, Snoop Tag, Spot Tag, SpyTag (Spy-Tag), Streptavidin Binding Peptide (SBP), Staphylococcal Protein A (Protein A), Staphylococcal Protein G (Protein G), StrepTag, Streptavidin (SBP-Tag), StrepTag II, Sdy-Tag, Small Ubiquitin-Like Modifier (SUMO),The tag may be selected from one or more of the following: tandem affinity purification (TAP), T7 epitope, tetracysteine ​​tag (TC tag), thioredoxin (Trx), TrpE, Ty tag, ubiquitin, universal, V5 tag, VSV-G or VSV-tag, and Xpress tag.

[0027] According to a further embodiment, there is provided a method for enzymatically removing A antigen from blood, red blood cells, or a donor organ, comprising the steps of (a) mixing a GalNAc deacetylase protein and a galactosaminidase protein with (1) blood containing A antigen, (2) type A or AB red blood cells, or (3) a donor organ presenting A antigen, and (b) incubating the enzyme with the (1) blood, (2) type A or AB red blood cells, or (3) the donor organ for a period of time sufficient for the enzyme to cleave the A antigen from the blood, red blood cells, or donor organ.

[0028] The GalNAc deacetylase may be a purified protein selected from one or more of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:17, SEQ ID NO:23, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34 and SEQ ID NO:35, and the galactosaminidase may be a purified protein selected from one or more of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:36, and SEQ ID NO:37.

[0029] The composition may comprise a purified enzyme having GalNAc deacetylase activity consisting essentially of an amino acid sequence at least 90% identical to one of SEQ ID NOs: 2, 4, 5, 17, 23, 29, 31, and 32-35, and a purified enzyme having galactosaminidase activity consisting essentially of an amino acid sequence at least 90% identical to one of SEQ ID NOs: 7, 9, 10, 19, 21, 36, and 37.

[0030] The GalNAc deacetylase can be a purified Flavonifractor platycii GalNAc deacetylase protein of SEQ ID NO:4 or SEQ ID NO:5, and the galactosaminidase can be a purified Flavonifractor platycii galactosaminidase protein of SEQ ID NO:9 or SEQ ID NO:10.

[0031] The method may further include adding a crowding agent, which may be selected from one or more of dextran, dextran sulfate, dextrin, pullulan, poly(ethylene glycol), Ficoll™, hyperbranched glycerol, and inert proteins.

[0032] The method may further comprise washing the blood, red blood cells or donor organ to remove GalNAc deacetylase, galactosaminidase and crowding agent.

[0033] The GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 1 μg / ml or less. The GalNAc deacetylase and galactosaminidase may have A antigen cleavage activity at a pH between about 6.5 and about 7.5. The GalNAc deacetylase and galactosaminidase may have A antigen cleavage activity at a temperature between 4° C. and 37° C.

[0034] According to a further embodiment, there is provided a blood collection and storage system comprising (a) a purified GalNAc deacetylase protein and (b) a purified galactosaminidase protein.

[0035] The system may further comprise a surface to which the enzyme is immobilized, the surface being selected from one or more of the following: (a) a bead or microsphere, (b) a container, (c) a tube, (d) a column, or (e) a matrix.

[0036] According to a further embodiment, a blood collection and storage device is provided, the device comprising: (a) a surface; (b) a purified GalNAc deacetylase protein immobilized on the surface; and (c) a purified galactosaminidase protein immobilized on the surface.

[0037] The device surface on which the enzyme is immobilized may be selected from one or more of the following: (a) beads or microspheres, (b) vessels, (c) tubes, (d) columns, (e) matrices. The vessel may be a bag.

[0038] GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 100 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 90 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 80 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 70 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 60 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 50 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 40 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 30 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 20 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 15 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 14 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 13 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 12 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 11 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 10 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 9 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 8 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 7 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 6 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 5 μg / ml or less.GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 4 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 3 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 2 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 1 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 0.9 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 0.8 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 0.7 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 0.6 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 0.5 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 0.4 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 0.3 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 0.2 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 0.1 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 0.09 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 0.08 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 0.07 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 0.06 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 0.05 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 0.04 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 0.03 μg / ml or less.GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 0.02 μg / ml or less. GalNAc deacetylase and galactosaminidase may be capable of cleaving the A antigen at 0.01 μg / ml or less.

[0039] GalNAc deacetylase and galactosaminidase may have A antigen cleavage activity at a pH between about 6.5 and about 7.5. GalNAc deacetylase and galactosaminidase may have A antigen cleavage activity at a pH between about 6.0 and about 8.0. GalNAc deacetylase and galactosaminidase may have A antigen cleavage activity at a pH between about 6.8 and about 7.8. GalNAc deacetylase and galactosaminidase may have A antigen cleavage activity at a pH between about 6.9 and about 7.9. GalNAc deacetylase and galactosaminidase may have A antigen cleavage activity at a pH between about 6.4 and about 7.8.

[0040] The GalNAc deacetylase and galactosaminidase may have A antigen cleavage activity at a temperature between 4°C and 37°C. The GalNAc deacetylase and galactosaminidase may have A antigen cleavage activity at a temperature between 3°C and 38°C. The GalNAc deacetylase and galactosaminidase may have A antigen cleavage activity at a temperature between 4°C and 40°C. The GalNAc deacetylase and galactosaminidase may have A antigen cleavage activity at a temperature between 4°C and 37°C. The GalNAc deacetylase and galactosaminidase may have A antigen cleavage activity at a temperature between 5°C and 37°C.

[0041] The purified GalNAc deacetylase and purified galactosaminidase may be immobilized. The purified GalNAc deacetylase may be immobilized. The purified galactosaminidase may be immobilized. The immobilized enzyme may be attached to a surface. The surface may be selected from one or more of a bead or microsphere, a container, a tube, a column, or a matrix. The surface may be selected from one or more of a container, a tube, a column, or a matrix. The container may be a bag.

[0042] According to another embodiment, a purified enzyme is provided comprising the Flavonifractor proutii GalNAc deacetylase of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:5.

[0043] According to another embodiment, there is provided a purified enzyme comprising the Flavonifractor platii galactosaminidase of SEQ ID NO:7, SEQ ID NO:9 or SEQ ID NO:10.

[0044] According to another embodiment, a purified enzyme is provided comprising a purified Clostridium tertium GalNAc deacetylase and a galactosaminidase fusion protein of SEQ ID NO:14.

[0045] According to another embodiment, there is provided a vector comprising a nucleic acid described herein and a heterologous nucleic acid sequence.

[0046] According to another embodiment, the method may be performed in vitro or ex vivo. As used herein, ex vivo means that the method is performed outside of an organism. For example, ex vivo includes ex vivo lung perfusion (EVLP) and treatment of donated blood. As used herein, ex vivo refers to an experiment or measurement or treatment performed in or on tissue or cells from an organism in an external environment with minimal or some change from the state in which the tissue or cells were placed when the tissue or cells were in vivo (e.g., red blood cells or donor organs). [Brief description of the drawings]

[0047] [Figure 1] FIG. 1 shows a schematic of cell surface antigen glycan structures terminating in α-1,3-linked N-acetylgalactosamine (GalNAc) or galactose (Gal) for types A, H and B, where triangles indicate the cleavage points of α-acetyl-galactosaminidase EmGH109 and α-galactosidase BfGal110. [Diagram 2] Figure 2 shows the deacetylase pathway for A antigen cleavage along with the corresponding mass spectrometry (MS) whereby Flavonifracter proutii (Fp) GalNAc deacetylase cleaves the acetyl group from the terminal α-N-acetyl-galactosamine of the A antigen (−42 m / z), and the galactosaminide intermediate is then cleaved by Flavonifracter proutii (Fp) galactosaminidase (−161 m / z). [Diagram 3] Figure 3 shows FACS analysis of A+ RBCs treated with different concentrations of EmGH109 or Flavonifractor platii GalNAc deacetylase (FpGalNAc deacetylase) + Flavonifractor platii galactosaminidase (Fp galactosaminidase) or treated for 1 h at 37 °C, anti-H antibody (added secondary FITC label) and APC-labeled anti-A antibody were used for visualization, the area of ​​appearance of H antigen is in the top left box. Columns A-D compare EmGH109 and FpGalNAcDeAc + FpGalNAc at 5 μg / ml (A), 10 μg / ml (B), 50 μg / ml (C), 50 μg / ml + dextran 40k (D). [Figure 4] Figure 4 compares EmGH109 and FpGalNAcDeAc+FpGalNase at different enzyme concentrations and at different temperatures (i.e., 4°C, room temperature (RT), and 37°C) in the presence (■) and absence (◆) of dextran. [Diagram 5]Figure 5 shows HPAE-PAD analysis of A+B+ and O+ erythrocyte cleavage products and a comparison of full-length Flavonifractor plati GalNAc deacetylase (FpGalNAcDeAc) + Flavonifractor plati galactosaminidase (FpGalNase) enzyme with the cleaved FpGalNAcDeAc + FpGalNase enzyme in A+ erythrocytes. [Figure 6] FIG. 6 shows the pH profile for each of (A) FpGalNAc deacetylase and (B) Fp galactosaminidase. [Figure 7] Figure 7 shows the conversion of A antigens to H antigens on A red blood cells analyzed via FACS for (A) A+ RBC control, (B) Flavonifractor platii GalNAc deacetylase (FpGalNAcDeAc) + Flavonifractor platii galactosaminidase (FpGalNase) (10ug / mL), (C) FpGalNAcDeAc + Clostridium tertium (Ct) Ct5757_GalNase (10ug / mL), and (D) FpGalNAcDeAc + Robinsoniella peoriensis (Rp) galactosaminidase (Rp1021) GalNase (10ug / mL). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0048] The following detailed description will be better understood when read in conjunction with the accompanying drawings, in which: For the purposes of illustrating the invention, the drawings show embodiments of the invention, but the invention is not limited to the precise arrangements, examples and instrumentalities shown.

[0049] Terms not directly defined herein are to be understood to have the meanings commonly associated with them as understood in the art of the invention.

[0050] As used herein, an "immobilized enzyme" is an enzyme attached to a surface, which may be an inert, insoluble material. Immobilization of enzymes can increase their resistance to changes in conditions such as pH, temperature, etc., and aid in their removal after use and for reuse of the enzyme.

[0051] Immobilization of enzymes may be achieved by a variety of methods (e.g., affinity tag binding, surface adsorption on glass, entrapment on resins, alginate beads or matrices, beads, fibers or microspheres, cross-linking to surfaces or other enzymes, and covalent binding to surfaces).

[0052] As used herein, "affinity tag binding" refers to the immobilization of an enzyme to a surface (e.g., a porous material using a non-covalent or covalent protein tag). Affinity tag binding has been used in protein purification and, more recently, in biocatalysis applications by EziG™ (ENGINZYME AB™, Sweden (e.g., PCT / US 1992 / 010113, and PCT / SE 2015 / 050108). Alternative systems for attaching active enzymes to surfaces are known in the art (see, for example, US4088538, US4141857, US4206259, US4218363, US4229536, US4239854, US4619897, US 4748121, US4749653, US4897352, US4954444, US4978619, US5154808, US5914367, US5962279, US6030933, US6291582, US6254645, US10,016,490, and US10,041,055).

[0053] Protein tags are peptide sequences genetically grafted onto recombinant proteins, often removable by chemical agents or enzymatic means, and attached to proteins for various purposes. The protein tags listed in Table A are intended to be examples and in no way limiting. One type of protein tag is an affinity tag, which is added to a protein or peptide sequence so that it can be purified from crude biological sources (e.g., from an expression system organism) using affinity techniques, or to facilitate immobilization of the "tagged" protein to a surface. Examples of affinity tags include chitin-binding domains (CBDs), maltose-binding proteins (MBPs), strep-tags, glutathione-S-transferase (GST), and polyhistidine (His-tags) that bind to metal matrices. Another type of protein tag is an epitope tag (e.g., V5-tags, Myc-tags, HA-tags, Spot-tags, NE-tags), which are short peptide sequences selected to facilitate the production of high-affinity antibodies, often derived from viral gene sequences to improve immunoreactivity. Epitope tags are also used to purify and immobilize proteins on surfaces, but are particularly useful for Western blotting, immunofluorescence and immunoprecipitation experiments. Yet another type of protein tag is the chromatographic tag (e.g., polyanionic amino acids such as the FLAG tag), which can be used to modify the chromatographic properties of proteins to aid in their separation and purification or immobilization. Yet another type of protein tag is the solubilization tag (e.g., maltose binding protein (MBP), glutathione S-transferase (GST), thioredoxin (TRX) and poly(NANP)) and the fluorescent tag (e.g., green fluorescent protein (GFP)). Protein tags allow for specific enzymatic modification, chemical modification, or binding of the protein to other components. However, depending on the type or number of tags added to the protein sequence, the original function of the protein, in this case the enzymatic function, may be impaired by the tag.Therefore, the protein tag must be selected to ensure that the activity of the enzyme is not compromised, or alternatively, the protein tag may be cleaved from the protein prior to use.

[0054] Table A: Representative protein tags JPEG2024163994000001.jpg150165JPEG2024163994000002.jpg180144JPEG20241639940 00003.jpg186138JPEG2024163994000004.jpg176142JPEG2024163994000005.jpg154148

[0055] The use of protein tags is exemplified in this application through the use of polyhistidine protein tags (His-tags) as set forth in SEQ ID NOs: 5, 10, 15, 17, 19, 21, 23, 25, 27, 29, and 31, although one of skill in the art will readily appreciate that any number of other protein tags can be used to purify enzymes and / or bind enzymes to surfaces as described herein, depending on the purification method used and / or the surface to which the enzyme is bound. Such protein tags can be selected from any one or more of the protein tags listed in Table A, although other such protein tags are known in the art.

[0056] Additionally, one or more cleavage sites (e.g., thrombin cleavage sites used in SEQ ID NOs: 15, 17, 19, 21, 23, 25, 27, 29, and 31) may be used to separate a protein tag from an enzyme or to otherwise cleave the enzyme. Cleavage sites may be used to remove an N-terminal methionine, a signal peptide, and / or convert an inactive or non-functional protein to an active protein (i.e., a zymogen or proenzyme). Alternatively, cleavage sites may be used to separate two or more enzymes expressed in the same reading frame. Examples of enzymes that can cleave proteins or peptides and would have sequence-specific cleavage sites may be selected from one or more of the following: Arg-C proteinase, Asp-N endopeptidase, Asp-N endopeptidase + N-terminal Glu BNPS-skatole, caspase 1, caspase 2, caspase 3, caspase 4, caspase 5, caspase 6, caspase 7, caspase 8, caspase 9, caspase 10, chymotrypsin high specificity (not before P, but at the C-terminus of [FYW]), chymotrypsin low specificity (not before P, but at the C-terminus of [FYWML]), clostripain (clostridiopeptidase B), CNBr, enterokinase, X a-factor, formate, glutamyl endopeptidase, granzyme B, hydroxylamine, iodobenzoate, LvsC, LvsN, NTCB (2-nitro-5-thiocyanbenzoate), neutrophil elastase, pepsin (pH 1.3), pepsin (pH > 2), proline endopeptidase, proteinase K, staphylococcal peptidase I, tobacco etch virus protease, thermolysin, thrombin, trypsin.

[0057] Those skilled in the art will understand that the combination of active galactosaminidase enzyme and active GalNAc deacetylase enzyme described herein that can efficiently cleave A antigen is important, and those skilled in the art will also understand that the addition of one or more cleavage sites and / or one or more protein tags is optional, and such modifications can be selected based on the specific expression system, purification system, and possible surface attachment strategy.In addition, other modifications to the galactosaminidase sequence and GalNAc deacetylase sequence are also possible, so long as the cleavage activity of A antigen is not significantly impaired.In addition, modifications to the galactosaminidase and GalNAc deacetylase sequence are possible, so long as the cleavage activity of A antigen is not significantly impaired.Modifications to the galactosaminidase and GalNAc deacetylase sequence can be deletions, insertions, and / or substitutions.Substitutions can be conservative or neutral substitutions.For example, the galactosaminidase sequence and GalNAc deacetylase sequence can share 90% or more sequence identity with the mature enzyme. For example, the galactosaminidase and GalNAc deacetylase sequences may share 85% or more sequence identity with the mature enzyme. For example, the galactosaminidase and GalNAc deacetylase sequences may share 75% or more sequence identity with the mature enzyme. Alternatively, the galactosaminidase and GalNAc deacetylase sequences may have up to 5, 10, 13, 15, 20, or 25% amino acid modifications.

[0058] As used herein, "adsorption to glass, alginate beads or matrices" refers to the attachment of an enzyme to the outside of an inert material. Generally, this type of immobilization does not occur by chemical reaction, and the active sites of the immobilized enzyme may be blocked by the surface to which it is adsorbed, which may reduce the activity of the adsorbed enzyme.

[0059] As used herein, "entrapment" refers to the entrapment of the enzyme within an insoluble bead or microsphere. However, entrapment can prevent the access of substrates and the egress of products. One example is the use of calcium alginate beads, which can be produced by reacting a mixture of sodium alginate and enzyme solutions with calcium chloride.

[0060] As used herein, "crosslinking" refers to the covalent binding of enzymes to each other to create a matrix that is almost entirely enzyme. When designing crosslinked enzyme reactions, ideally the binding sites do not cover the enzyme's active site, so that the enzyme's activity is only affected by the immobilization and not by the blockage of the enzyme's active site. Nevertheless, spacer molecules such as poly(ethylene glycol) can be used to reduce steric hindrance by the substrate.

[0061] As used herein, "covalently bonded" refers to the attachment of an enzyme to an insoluble support or surface (e.g., silica gel) via a covalent bond. Due to the strength of the covalent bond between the enzyme and the support or surface, it is highly unlikely that the enzyme will detach from the support or surface.

[0062] As used herein, "crowding agent" refers to any polymer or protein that promotes the aggregation of macromolecules by concentrating enzymes on the cell surface to improve the activity of the enzyme. Crowding agents can be, for example, dextran, dextran sulfate, dextrin, pullulan, poly(ethylene glycol), Ficoll™, hyperbranched glycerol, and inert proteins (Kuznetsova, IM et al. Int J Mol Sci. (2014) "What Macromolecular Crowding Can Do to a Protein" 15(12):23090-23140).

[0063] As used herein, "dextran" refers to a polysaccharide having a molecular weight of 1,000 daltons or greater and a linear backbone of α-linked d-glucopyranosyl repeating units. Dextrans are divided into three structural classes (i.e., classes 1-3) based on the pyranose ring structure, which contains five carbon atoms and one oxygen atom. Class 1 dextrans contain an α(1→6)-linked d-glucopyranosyl backbone modified with small side chains of d-glucose branches with α(1→2), α(1→3), and α(1→4) linkages. Class 1 dextrans vary in their molecular weight, spatial arrangement, type and degree of branching, and length of branching chains by 3-5, depending on the microbial production strain and culture conditions. Isomaltose and isomaltotriose are oligosaccharides with a class 1 dextran backbone structure. Class 2 dextrans (alternans) contain a backbone structure of alternating α(1→3)- and α(1→6)-linked d-glucopyranosyl units and α(1→3)-linked branches. Class 3 dextrans (mutans) have a backbone structure of consecutive α(1→3)-linked d-glucopyranosyl units with α(1→6)-linked branches.

[0064] As used herein, "pullulans" are structural polysaccharides produced primarily from starch by the fungus Aureobasidium pullulans and consist of repeating α(1→6)-linked maltotriose (D-glucopyranosyl-α(1→4)-D-glucopyranosyl-α(1→4)-D-glucose) units and occasionally containing maltotetraose units.

[0065] As used herein, "dextrin" refers to D-glucopyranosyl units beginning with a single α(1→6) linkage followed linearly by α(1→4) linked D-glucopyranosyl units and having a shorter chain length than dextran.

[0066] As used herein, "dextran sulfate" is derived from dextran through sulfation.

[0067] As used herein, "Ficoll™" is a neutral, highly branched, high mass hydrophilic polysaccharide that is readily soluble in aqueous solutions.

[0068] Various alternative embodiments and examples are described herein, which are illustrative and should not be construed as limiting the scope of the invention.

[0069] (material and method) Chemicals and commercial enzymes used in this study were purchased from Sigma-Aldrich™ unless otherwise noted. Monosaccharide methylumbelliferyl glycoside was a generous gift from Dr. Hongming Chen and A antigen subtype 1 penta-MU was a generous gift from Dr. David Kwan (Kwan et al. 2015).

[0070] Human fecal metagenomic library

[0071] For generation of human metagenomics fosmid libraries, blood group AB + Fresh human fecal samples were collected from healthy Asian male volunteers with HIV. Direct DNA extraction and fosmid library construction were performed according to the procedures described in the MoE protocol (Armstrong et al. 2017).

[0072] Fosmid library screening

[0073] 51 x 384 well AB +Blood fosmid library plates were thawed at room temperature and replicated in 384-well plates containing 50 μl of screening LB medium (12.5 μg / mL chloramphenicol, 25 μg / mL kanamycin, 100 μg / mL arabinose, 0.2% (v / v) maltose, 10 mM MgSO4). Plates were incubated for 18 h at 37 °C in a closed container containing a reservoir of water to prevent excessive evaporation. 45 μl of reaction mixture (100 mM NaH2PO4, pH 7.4, 2% (v / v) Triton-X100, 100 μM GalNAc-α-MU, 100 μM Gal-α-MU) was added onto the grown screening plates using a QFill™ device [Genetix™]. The plates were then incubated in a sealed container at 37°C for 24 hours and the fluorescence of each plate (ex: 365nm Em: 435nm, sweep mode, gain 80) was measured at 1, 2, 4, 8 and 24 hours via a SynergyH1 plate reader (BioTek™). For every well, a Z-score was calculated, given by the formula: Z-score = (median fluorescence) / standard deviation.

[0074] All positive hits above a certain threshold were rearranged onto a new 384-well plate, designated the "simple substrate hit" plate, and stored at -70° C. Two screening plates were replicated from the "simple substrate hit" plate and rescreened for either GalNAc-α-MU or Gal-α-MU activity to confirm and deconvolute the previously detected activity.

[0075] To determine which of the hits could cleave the A or B antigen structures, a coupled enzyme assay was used to assay the A antigen subtype 1 tetra-MU at 50 μM or the B antigen subtype 1 tetra-MU at 50 μM. 1tetra-We measured their activity against MU. A version of this binding assay was previously described by Kwan (Kwan et al. 2015). We modified the assay to detect cleavage of subtype 1A antigen by using BgaC (Jeong 2009) instead of BgaA (Singh 2014) as the binding enzyme. α-N-acetylgalactosaminidase and α-galactosidase cleave the terminal sugars and form the H antigen subtype I. tri- MU is released. Then, α-fucosidase (AfcA (Katayarna 2004)), β-galactosidase (BgaC (Jeong 2009)), and β-hexosaminidase (SpHex (Williams 2002)) exo-cleave the remaining sugars until 4-methylumbelliferyl alcohol is released, which can be detected as an increase in fluorescence. To achieve this, 50 μg / mL of each enzyme was added to the reaction mixture. All positive hits above a certain threshold were rescreened in triplicate, and a host cell line containing the vector lacking the insert was used as a negative control. All confirmed hits were stored separately in LB medium (12.5 μg / mL chloramphenicol, 25 μg / mL kanamycin, 15% (v / v) glycerol, 0.2% (v / v) maltose, 10 mM MgSO4) at -70 °C.

[0076] Fosmid hit sequencing

[0077] To isolate fosmid DNA for sequencing, positive hit fosmid glycerol stocks were used to inoculate 5 mL of TB medium (12.5 μg / mL chloramphenicol, 25 μg / mL kanamycin, 100 μg / mL arabinose, 0.2% (v / v) maltose, 10 mM MgSO4) and incubated overnight at 37 °C and 220 rpm. Fosmid isolation was performed using the GeneJet™ Plasmid Miniprep Kit (Thermo Fisher™). Isolated plasmids were purified from contaminating linear E. coli DNA using Plasmid-Safe™ ATP-dependent DNase (Epicentre™), followed by another purification using the GeneJet™ PCR Purification Kit (Thermo Fisher™). Concentrations were calculated using the Quant-iT™ dsDNA HS Assay Kit (Invitrogen™) on a Qbit™ fluorometer (ThermoFisher™). Expected DNA sizes were confirmed on a 1% agarose gel. 2ng of each fosmid was sent to the UBC Sequencing Center (Vancouver, BC, Canada) for complete fosmid sequencing. Each fosmid was individually barcoded and sequenced using an Illumina MiSeq™ system.

[0078] All Illumina MiSeq™ raw sequencing data were trimmed and assembled using Python scripts available on GitHub™ at https: / / github.com / hallamlab / FabFos. Briefly, reads were cleaned of adapters and low-quality sequences using Trimmomatic (Bolger 2014). These reads were screened for vector and host sequences using BWA (Li 2013) and then filtered to remove contaminants using Samtools™ and the bam2fastq script. These high-quality purified reads were assembled by MEGAHIT with k-mer values ​​ranging between 71 and 241, increasing by increments of 10 (Li 2015). These libraries often have over 20,000-fold coverage, and the minimum k-mer multiplicity was calculated by 1% of the estimated coverage of the fosmids to prevent accumulation of sequencing errors that would interfere with proper sequence assembly. Scaffolding was performed using minimus2 (Treangen 2011) outside of the Python script assembly which generates multiple contigs. Parameterized commands can be found both in the documentation on the GitHub™ page and in the Python script itself.

[0079] Fosmid ORF prediction and hit validation

[0080] Fosmid ORFs were identified using the metagenomic version of Prodigal™ (Hyatt 2010) and compared to the CAZy™ database using BLASTP™ as part of the MetaPathways™ v2.5 software package (Konwar 2015). MetaPathways™ parameters were: length >60, BLAST score >20, blast score ratio >0.4, E Value <1×10 -6 It is.

[0081] All predicted ORFs with annotation for members of the GH or CBM family (with known or suspected α-galactosidase and / or α-N-acetylgalactosaminidase activity) were cloned into the pET16b plasmid using the Golden Gate™ cloning strategy (Engler 2008) with primer sequences set out in Table B. Proteins were expressed in BL21(DE3) and cultured for 20 h at 37°C and 220 rpm in 10 mL of ZY5052 autoinduction medium (Studier 2005). Cells were harvested by centrifugation (4000×g, 4°C, 10 min) and resuspended in 1 mL of lysis buffer (100 mM NaH2PO4, pH 7.4, 2% (v / v) Triton-X™ 100, 1x Protease Inhibitor EDTA-free [Pierce™]). Ligation assays (Kwan 2015) were performed using 50 μl of crude cell lysate from candidates and 50 μl of assay buffer (100 mM NaH2PO4, pH 7.4, 50 μg / mL SpHex, 50 μg / mL AfcA, 50 μg / mL BgaC, 100 μM A antigen subtype 1tetra- The A and B antigens were mixed with 100 μM tetra-MU or 100 μM B antigen subtype 1 tetra-MU) and incubated at 37°C. All reactions were performed in triplicate in black 96-well plates. Fluorescence (365 / 435 nm) was continuously monitored for 4 h using a Synergy™ H1 plate reader (BioTek™). Assays from crude extracts showing cleavage activity against A or B antigens were repeated, this time without conjugated enzyme, and reaction products were isolated via HF Bond Elut C18 columns and analyzed by LC-MS and / or TLC. TLC was performed using TLC silica gel 60 F254 TLC plates (EMD Millipore Corp.™, Billerica, MA, USA).

[0082] Table B: Primer sequences JPEG2024163994000006.jpg211139

[0083] HPAE-PAD assay

[0084] The analysis of enzymatic release of galactosamine was performed on a HPAE-PAD (Dionex™) HPLC system. The cleavage activity of various proteins was tested on the following substrates: 7.5 μg / μL of porcine stomach type II mucin dissolved in 100 mM NaH2PO4 pH 7.4, 5 mM A antigen subtype 1 penta- MU in 100 mM NaH2PO4 pH 7.4 and RBCs (50% hematocrit) from A+, B+ and O-type donors in 1xPBS pH 7.4. Samples containing 10 μg / mL enzyme were incubated at 37°C for two hours and then stored at -80°C for further analysis. A small amount of the reaction (10 μl) was diluted in H2O (100 μl) and analyzed on the HPAE-PAD instrument. Separation was performed on a CarboPACPA200™ (150 mm) column with a guard column and detection was performed using a disposable gold on polytetrafluoroethylene (PTFE) electrode and a quadrupole waveform. Separation conditions were as follows: 100 mM sodium hydroxide and a sodium acetate gradient from 70 to 300 mM was applied over the first 10 minutes of the separation. The eluent was held at the final gradient conditions for 1 minute and returned to the initial conditions for the next minute. The flow rate was 1.0 ml / min, and injections were performed every 27 min. Standards of the free sugars GalNAc, Gal, and GalN (10 μM) were applied to the HPAE-PAD and peak elution times were determined for reference.

[0085] Kinetic assay

[0086] All kinetic assays using 4-methylumbelliferone as the leaving group were performed by measuring fluorescence. To avoid measurement errors due to the inner filter effect (Palmier 2007), a standard curve was used to verify the linear range of the fluorescent dye.

[0087] Fp galactosaminidase

[0088] Michaelis-Menten parameters for GalN antigen subtype 1 penta-MU and A antigen subtype 1 penta -MU was measured at 100 mM NaH2PO4, pH 7.4, 37°C. Reactions were performed with 3.4 nM Fp galactosaminidase (5.31 nM FpGalNase_truncA) and 0.1 mg / mL SpHex, AfcA, 0.2 mg / mL BgaC and various concentrations of substrate (5 μM to 2 mM) in 100 μl. A series of four reactions with a control (no Fp galactosaminidase) as a duplicate were performed. The fluorescence signal (365 / 435 nm) resulting from MU release by hydrolysis was monitored by a Synergy H1™ plate reader (BioTek™) and converted to concentration using a MU standard concentration curve measured under identical reaction conditions. Initial velocities (μM / s) were measured and plotted with Grafit 7.0™ to determine kinetic parameters.

[0089] k cat / K M The parameters were GalN antigen subtype 1 / 2 / 4. tetra- MU and B antigen subtype 1 tetra -MU was measured at pH 7.4 and 37°C. Reactions (100 μL total volume) were performed in black 96-plate wells with 8.63 nM Fp galactosaminidase, 0.1 mg / mL SpHex, BgaC (BgaA for subtype 2), AfcA, and various concentrations of substrate (25 μM, 20 μM, 15 μM, 10 μM, 7.5 μM, 5 μM) as binding assays in 100 mM NaH2PO4 (pH 7.4). A series of four reactions with a control (no Fp galactosaminidase) was performed as duplicates. Fluorescence signals (365 / 435 nm) resulting from MU release by hydrolysis were monitored by a Synergy H1™ plate reader (BioTek™) and converted to concentrations using a MU standard concentration curve measured under identical reaction conditions. Initial velocities (μM / s) were determined and plotted using Grafit 7.0™ to obtain k cat / K M (s -1 *mM -1 ) parameters were determined.

[0090] 863.2 nM Fp galactosaminidase (in 100 mM NaH2PO4, pH 7.4) or 369.9 nM FpGH4 (in 50 mM Tris / HCl, pH 7.4, 100 μM NAD) with various substrate concentrations (10 μM to 5 mM) in a volume of 100 μl. + Michaelis-Menten parameters were measured for GalN-α-pNP in clear 96-well plates with 1 mM MnCl2 (at 37°C). Reactions were performed as a series of three reactions with two controls (no enzyme). Absorbance (at 405 nm) resulting from pNP release by hydrolysis was monitored by a Synergy H1™ plate reader (BioTek™) and converted to concentration using a p-nitrophenol standard concentration curve measured under identical reaction conditions. Initial velocities (μM / s) were measured and plotted with Grafit 7.0™ to determine kinetic parameters.

[0091] FpGalNac deacetylase

[0092] A antigen subtype 1 in 100 mM NaH2PO4, pH 7.4, 37°C penta- For MU, Michaelis-Menten parameters were measured using a previously described binding assay (Kwan 2015). To detect cleavage of subtype 1 (later 4), we used BgaC (Jeong 2009) instead of BgaA (Singh 2014) as the β-galactosidase. penta-Since MU additionally contains galactose, the concentration of BgaC was increased to 0.2 mg / mL to compensate for the need to cleave both Gal-β-1,3-β-GlcNAc-β-1,3-Gal-β-MU and Gal-β-MU. In addition, Fp galactosaminidase was included to allow cleavage of galactosamine-containing intermediates. The reaction setup in 100 μl was 3 nM FpGalNAc deacetylase (4.52 nM FpGalNacDeAc_D1ext, 3.55 nM FpGalNacDeAc_D1+2) and 0.01 mg / mL Fp galactosaminidase, 0.1 mg / mL SpHex, AfcA, 0.2 mg / mL BgaC and various concentrations of substrate (5 μM to 2.5 mM). A series of four reactions with a control (without FpGalNac deacetylase) as a duplicate was performed. Fluorescence signals (365 / 435 nm) resulting from MU release upon hydrolysis were monitored on a Synergy H1™ plate reader (BioTek™) and converted to concentrations using a MU standard concentration curve measured under identical reaction conditions. Initial rates (μM / s) were determined and plotted with Grafit 7.0 to determine kinetic parameters.

[0093] k cat / K M The parameters are A antigen subtype 1 / 2 / 4 tetra-MU was determined at pH 7.4, 37°C. Reactions (100 μL total volume) were performed in black 96-well plates with 12 nM FpGalNAc deacetylase, 0.1 mg / mL SpHex, BgaC (BgaA for subtype II), AfcA, and various concentrations of substrate (25 μM, 20 μM, 15 μM, 10 μM, 7.5 μM, 5 μM) in 100 mM NaH2PO4 (pH 7.4) as binding assays. A series of four reactions with a control (no FpGalNAc deacetylase) was performed as duplicates. Fluorescence signals (365 / 435 nm) resulting from MU release by hydrolysis were monitored with a Synergy H1™ plate reader (BioTek™) and converted to concentrations using a MU standard concentration curve measured under identical reaction conditions. Initial velocities (μM / s) were determined and plotted with Grafit™ 7.0 to determine the kcat / KM (s-1*mM-1) parameter.

[0094] GH109 subtype dynamics

[0095] A antigen subtypes 1 / 2 / 4 tetra-The kcat / KM parameters were measured for MU at pH 7.4 and 37°C. Reactions (100 μL total volume) were performed in black 96-plate wells and binding assays were performed in 100 mM NaH2PO4, pH 7.4 with 86.02 nM BvGH109_1 / 100.49 nM EmGH109 / 80.52 nM BvGH109_2 / 87.4 nM BsGH109 and 5 μM NAD+, 0.1 mg / mL each for SpHex, BgaC (BgaA for subtype 2), and AfcA, and various concentrations of substrate (25 μM, 20 μM, 15 μM, 10 μM, 7.5 μM, 5 μM). A series of four reactions with a control (without α-N-acetylgalactosaminidase) were performed as duplicates. Fluorescence signals (365 / 435 nm) resulting from MU release by hydrolysis were monitored by a Synergy H1™ plate reader (BioTek™) and converted to concentrations using a MU standard concentration curve measured under identical reaction conditions. Initial rates (μM / s) were determined and plotted with Grafit 7.0™ to determine the kcat / KM (s-1*mM-1) parameter.

[0096] Crystallography

[0097] Prior to crystallization, FpGalNAcDeAc_D1ext was digested with thrombin (Novagen™) at a concentration of 1 mg / mL overnight using the manufacturer's suggested protocol. The protein was then purified by HisTrap FF column and the flow-through was collected, buffer exchanged into 10 mM Tris pH 8.0 + 75 mM NaCl, and concentrated to 12 mg / mL.

[0098] Crystallization

[0099] FpGalNAcDeAc_D1ext (12 mg / mL) was crystallized using the hanging drop diffusion deposition method with a reservoir solution consisting of 0.2 M CaCl2, 0.1 M MES pH 6, 18% PEG4000, and 20 mM MnCl2 at a protein:reservoir ratio of 1:1. A rapid bromide immersion was used to derivatize the crystals for phasing, and they were prepared by transferring the crystals to a solution of 1 M NaBr, 25% glycerol, 18% PEG4000, 20 mM CaCl2, and 0.1 M Mes pH for 30 s and flash freezing in liquid nitrogen. Crystal complexes with blood group B antigen trisaccharide (B_tri) were prepared by preincubating the protein (12 mg / mL) with 10 mM B_tri for 2 h, after which drops were set up under the same conditions as above, but omitting MnCl2. Crystals were cryoprotected in reservoir solution supplemented with 25% glycerol.

[0100] Data collection, phasing, and structure determination

[0101] The dataset was collected at the Canadian Light Source™. Data were integrated using XDS (Kabsch 2010) and scaled with Aimless™ (Evans 2013). Phasing and automated structure solution was performed using CRANK2™ (Skubak 2013) in the CCP4I2™ suite of programs (Potterton 2018). Structures were checked and refined using alternating cycles of Coot™ (Emsley 2004) and Refmac™ (Vagin 2004). The B_tri structural complex was solved by differential Fourier and the ligands were manually built in Coot™ as well as water and metal ions. Difference density maps revealed that the apo structure contained Mn 2+ , Ca in the coordination structure 2+The presence of was confirmed. The model was validated by Coot™ and Molprobity™ (Chen 2010). The atomic coordinates and structure factors of the apo and B_tri complexes have been deposited in the Protein Data Bank (PDB) with the following accession numbers: Flavonifructor platyphylla GalNAc deacetylase protein sequence number: WP_009260926.1, and Flavonifructor platyphylla galactosaminidase protein sequence number: WP_044942952.1.

[0102] Active site mutagenesis

[0103] Based on the structural information (not shown) and sequence alignment (not shown), FpGalNAcDeAc_D1min and FpGalNase_truncA were mutated using the QuickChange™ protocol (Zhang 2004) with the primers listed in Table B. The mutants were purified via NiNTA and HIC columns as described above. The structural integrity of all mutants was confirmed by CD spectroscopy, whereby all tested enzymes were structurally similar to the wild type. For mutants with relatively low activity, reactions were performed under the same conditions used for the complete kinetic determination. However, k cat / K M The values ​​were measured using the substrate consumption method as previously described (Vocadlo 2002). <K M (K m At low substrate concentrations (equivalent to ~1 / 5-1 / 10 of cat / K M Values ​​can be approximated by non-linearly fitting the reaction time course to a first-order curve and dividing by the enzyme concentration.

[0104] GH36 phylogenetic mapping

[0105] Reference sequences for GH36 were downloaded from the CAZy™ database using the SACCHARIS™ cazy_extract.pl script (Jones 2018). Reference trees were constructed and sequences were mapped to these trees using the phylogenetic-based protein profiling software, TreeSAPP™ (available at https: / / github.com / hallamlab / TreeSAPP). Briefly, protein family domains were extracted from all full-length sequences downloaded from CAZy™ (Yin 2012) using HMMs from dbCAN. These sequences were then clustered at 70% sequence similarity using UCLUST™ to remove redundant sequence space and reduce the size of the tree (Edgar 2010). RAxML™ version 8.2.0 was used to construct the reference tree, “--autoMRE” determined when to stop bootstrapping before 1000 replicates, and PROTGAMMAAUTO™ selected the best protein model (Stamatakis 2006 and Stamatakis 2008).

[0106] Query sequences were then mapped to these reference trees using TreeSAPP™. Briefly, protein sequences were aligned to HMMs using hmmsearch™ and aligned regions were extracted (Eddy 1998). hmmalign™ was used to include new query sequences into the reference multiple alignment, and TrimAl™ removed non-conserved positions from the alignment file (Capella-Gutierrez 2009). RAxML™ was used to sort query sequences in the reference trees by insertion. Alignments of each query sequence were filtered and concatenated into a single Jplace™ file before displaying with iTOL™ (Matsen 2012 and Letunic 2016).

[0107] RBC assay

[0108] Whole blood from healthy consenting donors was collected in citrate Vacutainers using a protocol approved by the Clinical Ethics Committee at the University of British Columbia. The tubes were spun at 1000×g for 4 min at room temperature to separate the RBCs and washed three times with 1xPBS pH 7.4. For assays in the presence of Dextran 40k, the washed RBCs (200 μL, 10% hematocrit) were placed in tubes and the supernatant was partially removed and replaced with 1xPBS pH 7.4 in the presence and absence of Dextran 40k (final concentration 300 mg / mL). Additionally, some assays were performed in 1xPBS pH 7.4 + 25% plasma or 100% plasma. The RBCs were carefully mixed and placed on an orbital shaker for 30 s. The diluted enzyme solution was then added to a final volume of 200 μL. The tubes were vortexed very gently and placed on an orbital shaker for the indicated time at the set temperature.

[0109] MTS Card

[0110] After the reaction, the RBCs were washed three times with excess 1xPBS pH 7.4 and analyzed using Micro Typing System™ (MTS) cards [MTS™, Florida, USA]. RBCs (12 μl, 5% hematocrit) suspended in diluent [MTS, Florida, USA] were carefully added to the column of minigel, leaving a space between the blood and the contents of the minigel. The MTS cards were centrifuged at 156xg for 6 min at room temperature using a Beckman Coulter Allegra X-22R™ centrifuge with the sample holder modified as recommended. The degree of antigen removal from the RBC surface was assessed from the position of the RBCs in the minigel after spinning, according to the manufacturer's instructions. RBCs with high surface antigen concentration were agglutinated upon interaction with the monoclonal antibodies present in the gel column and could not penetrate (MTS™ score 4). RBCs without surface antigen did not agglutinate and migrated to the bottom of the minigel (MTS score 0). RBCs that had undergone partial removal of surface antigens migrated to positions between these and were assigned a score between 0 (absent) and 4 (present) according to the manufacturer's instructions.

[0111] H antigen agglutination assay

[0112] To analyze the conversion of A antigen to H antigen after enzymatic treatment, washed A-ECO-RBCs were mixed with an equal volume of 2 μg / mL anti-H antibody (anti-blood group Hab antigen antibody [97-I]: cat no. ab24213 (Abcam™)) and monitored for the appearance of agglutination within a 30 min time frame. RBCs agglutinated with anti-H antibody were assigned a score between 0 (not agglutinated within 1800 s) and 5 (agglutinated within 120 s).

[0113] FACS

[0114] The enzyme-treated RBCs were washed twice with 1xPBS pH 7.4, and 1% hematocrit ECO-RBCs were treated with 1 / 100 APC-anti-A antibody (Alexa Fluor™ 647 mouse anti-human blood group A: cat no. 565384 (BD Pharmingen™)) and / or anti-H antibody (anti-blood group Hab antigen antibody [97-I]: cat no. ab24213 (Abcam™)) for 30 minutes at room temperature, then washed twice with 1xPBS pH 7.4. For detection of anti-H antibody, a secondary FITC-labeled antibody (goat F(ab′)2 anti-mouse IgM mu chain (FITC): cat no. ab5926 (Abcam™)) was used at 1 / 500 concentration. Data were evaluated after reconstitution in 1xPBS pH 7.4 (hematocrit 1%) using a flow cytometer (CytoFLEX™ (Beckman Coulter™)).

[0115] Enzyme adsorption and antigenicity

[0116] To test whether the enzymes could be easily removed from the treated RBCs, adsorption potential was evaluated: Pacific Blue-labeled FpGalNAc deacetylase and FpGalNase (F / P=1) were incubated with RBCs for 1 h at 37°C and, after several washes, the residual fluorescence was measured using a flow cytometer (CytoFLEX™ (Beckman Coulter™)).

[0117] Antigenicity was tested by incubating RBCs with 50 μg / mL of each enzyme, mixing the enzyme-treated RBCs with allogeneic or autologous serum, and observing the possibility of agglutination. In addition, to evaluate potential anti-IgG,-C3d exposure, the treated RBCs were tested with anti-IgG,-C3d MTS™ cards (MTS™, Florida, USA). The incubation time was 30 min at 37°C.

[0118] Synthesis of antigen subtypes

[0119] The synthesis of A and B antigen subtype 1 / 2 / 4 tetra-MU was carried out using a modified protocol described by Kwan (Kwan et al. 2015).

[0120] Two-step H antigen subtype 1 / 2 / 4 tri-MU synthesis

[0121] All three syntheses were carried out in 10 mL of 50 mM Tris / HCl, 200 mM NaCl, pH 7.4, 10 mM MnCl2, 50 U alkaline phosphorylase, 1.5 equivalents UDP-Gal, 1.2 equivalents GDP-Fuc (scaled to LacNAc-MU product) at a scale of 20 mg GalNAc-α-MU / GlcNAc-α-MU. Depending on the desired product, different glycosyltransferases were added at a concentration of 100 μg / mL: CgtBS42 and Te2FT for subtype I, HP0826 and WbgL for subtype II, and LgtD and Te2FT for subtype IV. The reaction was carried out at 37°C, the progress was controlled by TLC (mobile phase EtAc:MeOH:H2O ratio 6:2:1), 4-methylumbelliferone was hydrolyzed from the compound via 10% H2SO4 and detected by UV (360 nm). After no further product increase was observed, the reaction was applied to a HF Bond Elut C18 column, washed with several column volumes of 5% methanol, and the product was eluted with 25% methanol. The solvent was then removed under reduced pressure.

[0122] A antigen subtypes 1 / 2 / 4 tetra- MU synthesis

[0123] The final synthesis step is 10mg H antigen subtype 1 / 2 / 4 tri- A MU scale run was carried out in 5mL 50mM Tris / HCl, 200mM NaCl, pH7.4, 10mM MnCl2, 25U alkaline phosphorylase, 1.5 equivalents UDP-GalNAc and 100μg / mL BgtA at 37°C. After no further product increase was observed via TLC, the reaction was applied to an HF Bond Elut C18 column, washed with several column volumes of 5% methanol and the product eluted with 25% methanol. The solvent was then removed under reduced pressure. The final product was further purified on a 1.5x46cm HW-40F size cutoff column and then lyophilized.

[0124] B antigen subtypes 1 / 2 / 4 tetra- MU synthesis

[0125] The final synthesis step is 10mgH antigen subtype 1 / 2 / 4 tri- The MU scale was carried out in 5mL 50mM Tris / HCl, 200mM NaCl, pH7.4, 25U alkaline phosphorylase, 1.5 equivalents UDP-Gal and 100μg / mL BoGT6a at 37°C. After no further increase in product was observed, progress was followed via TLC, the reaction was applied to an HF Bond Elut C18 column, washed with several column volumes of 5% methanol and the product was eluted with 25% methanol. The solvent was then removed under reduced pressure. The final product was further purified on a 1.5x46cm HW-40F size exclusion column and then lyophilized.

[0126] GalN antigen subtype 1 penta- MU synthesis

[0127] 10 mg of A antigen subtype 1 penta-MU was incubated with 1 μg / mL FpGalNAc deacetylase in 5 mL of 100 mM NaH2PO4 for 30 min at 37 °C, after which the reaction was stopped by adding 1 mM EDTA, complete conversion of the substrate was confirmed by TLC, the reaction was applied to an HF Bond Elut C18 column, washed with several column volumes of 2% methanol, and the product was eluted with 10% methanol. The solvent was then removed under reduced pressure.

[0128] Protein purification

[0129] All proteins and truncations were cloned into pET16b or pET28a via Golden Gate™ cloning (Engler 2008) or PIPE cloning (Klock 2008). Primer sequences are listed in Table B.

[0130] Protein production for extended characterization was performed in BL21(DE3) cells grown for 20 h at 37°C and 220 rpm in 200 mL of ZY5052 autoinduction medium (Studier 2005) and inoculated into 100 μl of an overnight LB culture. Cells were harvested by centrifugation (4000xg, 40°C, 10 min), resuspended in 10 mL lysis buffer (50 mM Tris / HCl, 150 mM NaCl, 1% (v / v) glycerol, 40 mM imidazole, pH 7.4, 2 mM DTT, 1x protease inhibitor EDTA-free (Pierce™), 2 U Benzonase (Novagen™), 0.3 mg / mL lysozyme, 10 mM MgCl2) and then sonicated on ice (3 min pulse time; 5 s pulse, 10 s pause, 35% amplitude). After removal of cell debris by centrifugation (14000xg, 4°C, 30 min), the supernatant was collected and loaded onto a nickel affinity chromatography column (5 mL HisTrapHP™ column (GE™)) using a peristaltic pump. Elution was performed on an AEKTApurifier™ system (GE™) and monitored via SDS-PAGE with a 10-75% gradient of 50 mM Tris / HCl, 400 mM imidazole, pH 7.4, 2 mM DTT to identify fractions containing protein, which were then pooled. Buffer exchange into 50 mM Tris / HCl, 150 mM NaCl, pH 7.4, 2 mM DTT and concentration were performed in Amicon Ultra-15 Centrifugal Filter Units™ MWCO 10 kDa (Millipore™).

[0131] FpGalNAc deacetylase, Fp galactosaminidase and its cleavage required a second round of purification, and Amicon Ultra-15 Centrifugal Filter Units MWCO 10 kDa (Millipore™) were used to exchange the buffer before loading the proteins onto a hydrophobic interaction chromatography column (Phenyl Sepharose High Performance Column 10 mL (Pharmacia Biotech™)). Column loading, washing and elution (gradient 0-100%) were processed through an AEKTApurifier (GE™) utilizing the following buffer conditions: FpGalNAc deacetylase, bind 1xPBS, 800 mM NH2PO4, pH 7.4 and elute 1xPBS, pH 7.4 and Fp galactosaminidase, bind 25 mM Tris / HCl, 1 M NaCl, pH 7.4, elute 25 mM Tris / HCl pH 7.4. Fractions containing the proteins were identified by SDS-PAGE and then pooled. Buffer exchange into 50 mM Tris / HCl, 150 mM NaCl, pH 7.4 and concentration were performed in Amicon Ultra-15 Centrifugal Filter Units™ MWCO 10 kDa (Millipore™).

[0132] Protein characterization

[0133] Optimal pH value

[0134] A antigen subtype 1 penta- MU and GalN antigen subtype 1 penta- The general pH ranges for activity of FpGalNAc deacetylase and Fp galactosaminidase towards MU were determined by the appearance of the product on TLC plates for different pH values, respectively. Reactions were carried out at 100 μl scale, at 37 °C, with 50 μM substrate and 1 μg / mL enzyme in the appropriate buffer systems. Buffers for pH 4-6 were based on 50 mM citric acid / sodium citrate buffer, for pH 6-8 50 mM sodium phosphate buffer and for pH 8-10 50 mM glycine / sodium hydroxide buffer.

[0135] To determine the optimal pH value, 5 μg / mL of Fp galactosaminidase was incubated in 100 μl of 50 mM sodium phosphate buffer over a range of pHs (5.8–8.0) with 200 μM GalN-α-pNP, and the absorbance (at 405 nm) resulting from pNP release was monitored for 1 h at 37°C by a Synergy H1™ plate reader (BioTek™).

[0136] 5 μg / mL FpGalNAc deacetylase and 50 μM A antigen subtype Ipenta-MU were pre-incubated for 10 min at 37 °C in 25 mM sodium phosphate buffer at various pH ranges (5.8-10.0). The reaction was quenched with 100 mM sodium phosphate buffer pH 7.5, 100 μM EDTA, 5 μg / mL Fp galactosaminidase, 50 μg / mL SpHex, 50 μg / mL AfcA and 50 μg / mL BgaC in a final volume of 100 μl. The fluorescent signal (365 / 435 nm) resulting from MU release by hydrolysis was monitored for 30 min at 37 °C by a Synergy H1™ plate reader (BioTek™).

[0137] Protein stability

[0138] FpGalNAc deacetylase and FpGalNase were stored in 1x PBS buffer, pH 7.4, at 4°C. After 2 and 12 weeks, A antigen subtype 1 penta- The enzyme activity was tested in the coupled enzymatic reaction of GalN-α-pNP for FpGalNAc deacetylase and FpGalNase as described for the pH optimum for MU.

[0139] FpGalNAc deacetylase inhibition

[0140] FpGalNAc deacetylase was tested against different potential inhibitors in a 96-well plate format as a binding assay. Reactions were performed at 37°C in 100 μL scale with 50 μM A antigen subtype 1 penta-MU and 5 μg / mL FpGalNAc deacetylase in 100 mM NaH2PO4 pH 7.4 with 10 μg / mL Fp galactosaminidase, 50 μg / mL SpHex, 50 μg / mL AfcA, and 50 μg / mL BgaC. The following inhibitors were tested: EDTA (1, 10, 100 μM), Marimastat (1, 10, 100, 1000 μM), DMSO (2%, 4%), Protease Inhibitor Cocktail EDTA-free (Pierce™) (1x, 2x, and 4x). Fluorescence (365 / 435 nm) was continuously monitored for 1 h using a Synergy H1™ plate reader (BioTek™). Additives showing strong effects were retested without bound enzyme and product formation was analyzed by TLC.

[0141] Limited decomposition

[0142] To determine whether there is a smaller, more stable subdomain of Fp galactosaminidase, limited proteolysis was performed. Fp galactosaminidase was treated with thermolysin (protein:protease mass ratio 10:1) at various temperatures (20 °C, 37 °C, 42 °C, 50 °C, and 65 °C) for 1.5 h. Samples were then run on an SDS-PAGE gel and a stable fragment was identified migrating at approximately 70 kDa (from the initial 118 kDa), with nearly complete degradation being achieved at an incubation temperature of 50 °C. This fragment was sent to the UBC Proteomics Core Facility for peptide identification and was determined to be a C-terminal truncated form of the full-length protein with a cleavage site between amino acids 690 and 700.

[0143] Glycan array screening

[0144] For glycan array screening, 500 μg of FpGalNAcDeAc_D2ext was labeled with fluorescein isothiocyanate (FITC) using the Fluorotag™ FITC conjugation kit (Sigma™) at an F / P ratio of 1. Screening was performed on CFG's Protein-Glycan Interaction Core Facility™ version 5.3 printed arrays composed of 600 glycans in six replicates for protein concentrations of 5 and 50 μg / mL. Analysis of binding motifs was performed using a web tool from Emory University (https: / / glycopattern.emory.edu / ).

[0145] (Example) Example 1: Construction and screening of metagenomic libraries

[0146] A.B. +We constructed a metagenomic library containing large (35-65 kb) fragments of DNA extracted from fecal samples provided by male donors of blood type 1 and 2. Such libraries contain multiple genes per bacterium, increasing the probability of expression of at least some of these genes and allowing expression of small "pathways" of multiple genes. Our library contained approximately 19,500 clones in 51 × 384 well plates, potentially about 800,000 genes, and therefore initial screening of such a library with expensive A-antigen substrates was impractical. Rather, we screened with the simple and sensitive fluorogenic substrates methylumbelliferyl α-glycosides of galactose and N-acetyl-galactosamine (Gal-α-MU and GalNAc-α-MU). An initial screen mixing the two substrates yielded a subset of 226 hits. These were rescreened against each individual substrate, and 44 were identified with GalNAcase and 166 with galactosidase activity. A second round of screening was performed on these hits using the coupled enzyme assay (Kwan 2015) with the A and B antigen tetrasaccharide glycoside substrates shown in Figure 1, along with a control group in which no substrate was present: only if the first Gal or GalNAc is cleaved can the coupled enzyme act and release MU. Eleven of these hits contained A antigen cleavage activity, one of which also cleaved the B antigen, while six produced fluorescence in the absence of substrate, thus encoding pathways that generate unrelated fluorescent products.

[0147] Example 2: Sequencing and initial analysis of hits

[0148] Eleven plasmids were sequenced on an Illumina MiSeq™ and ORFs present in the CAZy™ database (http: / / www.cazy.org / ) (Lombard 2014) were identified using the Metapathways™ software (Konwar 2015). Due to the considerable depth of human microbiome sequencing currently available, it was possible to identify the organisms from which all fosmids originated. Eight of the eleven species were derived from overlapping fragments of the genomes of two species of the Bacteroides genus, and the sequences could be grouped into five clusters. The only gene common to all fosmids in cluster B is the GH109 enzyme (B. vulgatus). Cluster A also contains GH109 (B. stercoris), but GH109 is the only CAZy gene found in other Bacteroides-derived fosmids (B. vulgatus). Fosmid N08 from the obligate anaerobe Flavonifractor proutii (Li 2015) contains three ORFs found within CAZy, namely the apparent glycan-binding module CBM32 and two potential glycoside hydrolases GH36 and GH4. Finally, fosmid K05 from Collinsella sp., presumably Collinsella tanakaei, does not contain any CAZy-related ORFs. Here, generation of a sublibrary of fosmid K05 allowed the identification of an ORF with A-cleavage activity, which was later identified as GH36 (not shown).

[0149] Example 3: Analysis of GH109 enzymes

[0150] The GH109 family was discovered based on the A antigen cleavage activity of some of its members. These enzymes recognize an unusual NAD +The enzymes use a GH4-dependent mechanism that was first discovered for the enzyme in GH4 Add Yip Ref (2004) J. Amer. Chem. Soc. 126, 8354-8355, which demonstrated the mechanism (Varrot 2005 and Liu 2007). The three GH109 genes identified here were cloned with a His tag after removal of the signal peptide and expressed in Escherichia coli BL21 (DE3). The three proteins, BsGH109, ​​BvGH109_1 and BvGH109_2 (not shown), were purified together with the standard GH109 from Elizabethkingia meningosepticum (EmGH109) (Liu 2007) as a standard, and kinetic parameters were determined for each. The three novel enzymes showed similar catalytic efficiency for each of the three A-subtype substrates tested, largely reflecting the kinetic parameters of the EmGH109 standard. In contrast, with an approved MTS card, + Unfortunately, only EmGH109 showed significant activity when their A antigen cleavage activity was tested on RBCs. The test was performed in the presence of dextran 40K as a crowding agent, which has been shown to increase activity by concentrating the enzyme on the cell surface (Chapanian 2014). In its absence, even 150ug / mL of EmGH109 was ineffective, but in the presence of 300mg / mL of dextran 40K, 15μg / mL of the enzyme was sufficient (see Figures 3 and 4). Previous studies have shown that low ionic strength also enhances the activity of EmGH109 on cells (Liu 2007). Thus, EmGH109 is not effective in whole blood.

[0151] Example 4: Analysis of GH36 from fosmid K05 from Collinsella sp.

[0152] The GH36 protein identified in fosmid K05 (named K05GH36) showed activity against GalNAc-α-MU and the A-antigen tetrasaccharide. This is consistent with its membership in the GH36 family, which primarily contains α-galactosidase and α-N-acetylgalactosaminidase, and which performs hydrolysis by a dual-displacement mechanism involving a covalent β-glycosyl enzyme intermediate (comfort 2007). Phylogenetic analysis placed the sequence within cluster 4 of the GH36 subfamily (Fredslund 2011). Interestingly, this cluster also contains in close proximity a characterized GH36 from Clostridium perfringens, which is also known to cleave the A-antigen structure (Calcutt 2002). However, when the ability of K05GH36 to remove the A-antigen from erythrocytes was tested, its activity was disappointing, scoring only 3, even when combined with crowding agents.

[0153] Example 5: Analysis of fosmid N08 from Flavonifractor proutii

[0154] As these novel enzymes offered no advantage, we focused on the N08 fosmid from F. proutii, specifically because its gene product cleaves both A and B antigens. We cloned the three CAZ-related genes, removed their signal peptide sequences, expressed them in E. coli BL21(DE3), and purified the resulting enzymes with yields up to 140 mg / L. Surprisingly, when we tested the individual purified proteins against A and B tetrasaccharide substrates, the only cleavage observed was that of the B antigen by N08GH36, and no cleavage of the A antigen by any of them. For this reason, we tested pairwise combinations of these enzymes and were surprised to find that a mixture of N08CBM32 and N08GH36 rapidly cleaved the A antigen tetrasaccharide. TLC analysis of the reaction mixtures with the individual enzymes revealed that N08CBM32 catalyzed the conversion of the A antigen to a more polar, but still UV-active, product, while subsequent addition of N08GH36 released a sugar product that co-migrated with galactosamine along with the H antigen trisaccharide. MS analysis of the reaction mixtures showed that N08CBM32 is an A antigen deacetylase, thus the 42 m / z and the reduction of the more polar product, while N08GH36 is a galactosaminidase, a novel activity in this family (Figure 2). This was further confirmed by high performance anion exchange chromatography (HPAE-PAD) analysis of the reactions (Figure 5), which showed that treatment of the A antigen with both enzymes, but not with the individual enzymes, released galactosamine. Similar results were obtained with a gastric mucin substrate for which the enzyme was probably evolved. Therefore, the two enzymes are hereafter referred to as FpGalNAc deacetylase (FpGalNAcDeAc) and Fp galactosaminidase (FpGalNase).

[0155] This pathway of A antigen degradation has not been previously characterized but, interestingly, was suggested more than 50 years ago as an explanation for the so-called “acquired” B phenomenon, in which type A patients infected with Clostridium tertium underwent an apparent change in blood type to type B (Gerbal 1975), as did forensic samples of human tissue submerged in the River Thames (Ref Judd and Annesley https: / / doi.org / 10.1016 / S0887-7963(96)80087-3,Transfusion medicine reviews(1996)10,111-117). This was probably because the anti-B antibodies used for typing were unable to distinguish between terminal Gal and GalN.

[0156] We investigated the third enzyme in the fosmid, GH4, and found that it hydrolyzes Gal-α-pNP, GalN-α-pNP, and GlcN-α-pNP, but does not cleave A-antigen-based substrates. It therefore does not appear to be directly involved in the conversion of the A-antigen. However, these glycosaminidases represent a novel activity within the GH4 family.

[0157] Example 6: Characterization of FpGalNAc deacetylase

[0158] More detailed bioinformatic analysis of this gene by Phyre2™ (Kelley 2015) showed that it has a ~308 amino acid domain of previously unknown function at the N-terminus and a ~145 amino acid CBM32 near the C-terminus with a linker region in between. Cleavage analysis confirmed this basic structure, as all constructs containing the intact deacetylase domain indeed showed catalytic activity (Table 2). Thus, this protein is classified as the founding member of a new glycoesterase family, CExx.

[0159] It has been demonstrated that all acetamido sugar deacetylases are metalloenzymes that require divalent metal ions (Blair 2005). Consistent with this, treatment with 100 μM EDTA almost completely abolished the enzyme activity, but Mn 2+ , Co 2+ , Ni 2+ or Zn 2+ The activity of the enzyme increased with the addition of 100 mM NaCl. Other inhibitors of (non-metal)amidases were ineffective. The enzyme has a pH optimum around 8 (Figure 6) and its substrate specificity is narrow, restricted to the different A subtypes and shorter versions. However, within these subtypes it is poorly differentiated, with only about a two-fold difference in specific activity between all of these subtypes (Table 2). Such a pH-dependence and specificity profile is ideal for RBC conversion, since all A subtypes are deacetylated, but none are otherwise.

[0160] The specificity of the CBM portion of the protein was investigated using glycan arrays from the Consortium for Functional Glycomics (CFG). The preferred targets were glycans with repeating N-acetyllactosamine (LacNAc) structures, as also seen for the founding member of the CBM32 family, the N-acetylglucosaminidase from Clostridium perfringens (Ficko-Blean 2006). However, unlike CBMs, our compositions do not show high affinity binding to blood antigen structures. Repeating LacNAc structures are common components of cell surfaces as common components of complex and hybrid N-glycans, as well as some O-glycans and glycolipids (Cohen 2009). In our case, these probably serve as anchor points for the deacetylase domain to bind. This brings its catalytic domain into close proximity to the A antigen without competing with its own substrates. In support of this model, removal of the domain reduced activity in RBCs without affecting the rate of cleavage of soluble substrates (Table 2).

[0161] Example 7: Crystallographic analysis of FpGalNAc deacetylase

[0162] To provide structural insight into this novel enzyme activity, the truncated proteins were subjected to crystallization studies and found that FpGalNAcDeAc_D1ext produced crystals that diffracted to the best resolution. Solution of this structure revealed a catalytic domain that adopts a five-fold β-propeller configuration with an active site that contains a divalent metal ion coordinated by D100 and H252. Co-crystallization of the enzyme with the B antigen trisaccharide as an analogue of the reaction product revealed its binding mode. At the base of the active site pocket, the non-reducing terminal galactosyl moiety, which distinguishes A and B antigens, makes hydrogen-bonding interactions with H97, E64 and two metal-coordinated waters. The remaining ligands are surface-exposed, and polar interactions between the fucosyl group and the S61 and D121 side chains are identified. As the C1-OH group of the reducing terminal galactosyl moiety is solvent exposed, extension to the substrate (i.e., at GlcNAc) is easily accommodated by the enzyme. Modeling the N-acetyl group of the A-trisaccharide onto this structure allowed us to make rational mutations of nearby amino acids that may be involved in deacetylation of the substrate. Residue E64 was found to be important for activity, with both mutants being inactive, suggesting a likely direct role in activating the nucleophilic water molecule (Table 1). Residues coordinating the divalent metal D100, Y315, and H252 were also found to be important, with both mutations resulting in approximately 5000-fold rate reductions consistent with their apparent role in binding divalent metal ions. By analogy with other acetamido sugar deacetylases, we propose that FpGalNAc deacetylase carries out hydrolysis by a mechanism that polarizes the carbonyl and activates a water molecule for nucleophilic attack on the carbonyl to form a tetrahedral intermediate. Resolution of this intermediate is facilitated by proton donation to the sugar nitrogen atom by His100.

[0163] Table 1|A antigen Type2 tetra Specific activity of FpGalNAcDeAc_D1min and its mutants for cleavage of -MU JPEG2024163994000007.jpg77153

[0164] Example 8: Characterization of FpGalNAcDeAc and FpGalNase

[0165] Phylogenetic analysis of the sequences placed FpGalNase in a new subgroup (5) of the GH36 family (Fredslund 2011). A 390 amino acid catalytic domain is located in the center of this large (1079 amino acids) protein, with a potential carbohydrate-binding domain at the C-terminus. Removal of this C-terminal domain did not affect the kinetic parameters of the enzyme with soluble substrates (Table 2), but did not affect the deacetylase A activity. + This enzyme is specific for galactosamine-containing sugars and does not cleave GalNAc residues under any circumstances tested. However, it has a fairly broad specificity for cleaving de-N-acetylated galactosaminides ranging from the simple aryl glycoside GalN-α-pNP to higher ones. Indeed, (Table 2) k cat / K M The values ​​were all similar to each other and to the values ​​for the deacetylases. k for cleavage of the B antigen cat / K M The value of was more than 2000-fold lower than that for the corresponding GalN antigen, but was nevertheless sufficient to generate a positive hit in the original screen. This specificity for deacetylated α-galactose constitutive substrates, combined with its pH optimum of approximately 6.5-7.0, makes it suitable for use in blood group conversion together with deacetylases (Figure 6).

[0166] Table 2 | Kinetic parameters of FpGalNAcDeAc and FpGalNase constructs towards different antigenic substrates JPEG2024163994000008.jpg149160

[0167] Example 9: Cleavage of A antigen from RBCs

[0168] A + , B + and O + Type A RBCs were incubated with FpGalNAcDeAc and FpGalNase, respectively, and in a mixture, and the released sugars were analyzed by HPAE-PAD ion chromatograms. Neither enzyme used individually released any sugar products. However, when the mixture of both was used, galactosamine was released only in type A RBCs. + Apparently released from RBC, but B + Or O + The GalNAc was not released from the RBC surface and showed high specificity only for the A antigen. This is very significant because it indicates that GalNAc is not released from the RBC surface in other situations. A truncated form of FpGalNase was also effective, but with slightly lower activity.

[0169] Next, antigen removal from RBCs was tested using industry standard MTS™ cards. RBCs are loaded onto these antibody-binding columns and spun in a centrifuge. RBCs without antigen move to the bottom of the column and are scored as 0, whereas untreated RBCs with the corresponding antigen adhere to the top and are scored as 4, with intermediate scores ranking the extent of antigen removal. Treatment with FpGalNase alone, at concentrations (Table 3), did not remove A or B antigenicity, consistent with its inactivity towards GalNAc substrates and low activity towards Gal. Incubation with FpGalNAcDeAc removes antigenicity by conversion of acetamide to amine, weakening the binding of the anti-A antibody used. The minimum amount of enzyme required for complete antigen deacetylation was evaluated with FpGalNAcDeAc alone and in combination with FpGalNase, both with and without 300 mg / ml dextran as a crowding agent. Amounts of FpGalNase up to 3 μg / ml were sufficient without dextran, but including 300 mg / ml dextran reduced the required loading to 0.5 μg / ml (Table 3). The previous best enzyme, EmGH109, ​​was ineffective in the absence of dextran unless a low-salt buffer was used, but in the presence of dextran the minimum effective concentration was 15 μg / ml, a 30-fold higher loading. A version of FpGalNAcDeAc lacking the CBM was much less effective.

[0170] Table 3|A + , B + and A.B. + MTS card results when RBCs were treated with EmGH109, ​​FpGalNAcDeAc and FpGalNase JPEG2024163994000009.jpg140156

[0171] Because the MTS™ card test does not assess the complete conversion of A antigens, and because antibodies to detect GalN antigens were not available, we focused on the detection of newly formed H antigens on the processed RBCs. FpGalNase was functional at a concentration of only 5 μg / ml, leading to a concomitant increase in H antigen levels with a loss of A antigens, as confirmed by the FACS analysis seen in Figure 3. By measuring the agglutination time in the presence of anti-H antibodies, we were able to detect the agglutination of several A antigens. + We demonstrated functionality of both enzymes on RBC donors and in whole blood reaction conditions that have not been achieved with other blood converting enzymes. Thus, this enzyme pair demonstrates the ability to perform A at a much lower enzyme loading than required for the best current enzymes. + RBCs are converted to type O "universal donor" RBCs. However, before these RBCs are transfused to a patient, it is recommended that all traces of the enzyme used in the conversion are removed, most likely by washing of the cells after centrifugation, to avoid adverse immune reactions. To confirm that this can be achieved, fluorescently labeled samples of FpGalNAcDeAc and FpGalNase are used to transfect the RBCs. + Processing of RBCs followed by FACS analysis confirmed that the simple washing was indeed effective (Figure 3).

[0172] Further characterization of the produced A-ECO RBCs may be useful to assess their full viability for use in transfusion medicine, but the possibility of including the enzyme directly in the plasma, potentially during collection of blood donations, may allow for an easy and cost-efficient implementation into existing automated routines of blood collection and storage, leaving the process. Notably, the stability of the enzyme was tested, as shown in Table 4. Table 4: Storage stability of galactosaminidase and GalNAc deacetylase JPEG2024163994000010.jpg92157

[0173] Example 10: GalNAc deacetylase and galactosaminidase fusion from Clostridium tertium

[0174] In our search for similar enzymes, we identified a novel Clostridium tertium natural fusion of galactosaminidase and GalNAc deacetylase linked by a CBM (GH36 domain-CBM-deacetylation domain). Initial studies showed that this enzyme cleaves A antigen on erythrocytes (same mechanism of first deacetylation and then galactosamine cleavage), but not as efficiently (i.e., similar to EmGH109). Although the Clostridium tertium deacetylation domain is not as efficient as the F. platii GalNAc deacetylase, when assisted by the F. platii GalNAc deacetylase, the Clostridium tertium galactosaminidase domain shows activity on erythrocytes similar to that of F. platii galactosaminidase.

[0175] Example 11: Alternative GalNAc Deacetylase and Galactosaminidase Enzymes

[0176] The data indicate that Clostridium tertium galactosaminidase (Ct5757_GalNAse) and Rp1021 have comparable enzymatic activity for the conversion of GalN antigen to H antigen (second reaction step).

[0177] Data was also collected for alternative GalNAc deacetylase and galactosaminidase enzymes and the alternative enzymes were compared to Flavonifractor proutii GalNAc deacetylase and Flavonifractor proutii galactosaminidase. As shown in Table 5, MTS scores for anti-A antibodies on processed A RBCs are shown for a Clostridium tertium native fusion of galactosaminidase and GalNAc deacetylase, which requires the presence of dextran to effectively cleave the A antigen and also shows good activity (Ct5757_DeAcase) when combined with Flavonifractor proutii galactosaminidase (FpGalNase). Also in Table 6, the data show that Robinsoniera peoriensis (Rp) Rp3672 and Rp3671 were able to deacetylate A antigens on RBCs, but less efficiently than FpGalNAcDeAcase, and activity was only achieved in the presence of a crowding agent (i.e., dextran 40k).

[0178] Table 5: MTS scores of anti-A antibodies on processed A RBCs JPEG2024163994000011.jpg53153

[0179] Table 6: MTS scores of Robinsoniella peoriensis (Rp) 3671 and 3672 JPEG2024163994000012.jpg36148

[0180] Figure 7 shows the conversion of A antigen to H antigen on A RBCs analyzed by FACS sorting for (A) A+ RBC control, (B) Flavonifractor platii GalNAc deacetylase (FpGalNAcDeAc) + Flavonifractor platii galactosaminidase (FpGalNase) (10 μg / mL), (C) FpGalNAcDeAc + Clostridium tertium (Ct) Ct5757_GalNase (10 μg / mL), and (D) FpGalNAcDeAc + Robinsoniera peoriensis (Rp) galactosaminidase (Rp1021) GalNase (10 μg / mL). The data show that Clostridium tertium (Ct) Ct5757_GalNase and Robinsoniaella peoriensis (Rp) galactosaminidase (Rp1021) GalNase show comparable enzymatic activity for the conversion of GalN antigen to H antigen (second reaction step) as Flavonifractor platii galactosaminidase.

[0181] Although various embodiments of the present invention are disclosed herein, many adaptations and modifications can be made within the scope of the present invention, according to the general knowledge of those skilled in the art, including the substitution of known equivalents for any aspect of the present invention to achieve the same result in substantially the same way. Numerical ranges are inclusive of the numerical values ​​defining the range. As used herein, the term "comprising" is used as an open-ended term substantially equivalent to the phrase "including, but not limited to," and the word "comprises" has a corresponding meaning. As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a thing" includes a plurality of such things. Citation of a reference herein is not an admission that such reference is prior art to an embodiment of the present invention. The present invention includes all embodiments and variations substantially as described above with reference to the examples and drawings.

[0182] (array) The Flavonifractor proutii DNA sequence was modified from the naturally occurring DNA sequence (GalNAc deacetylase 2311 / 2319nt / galactosaminidase 3228 / 3237nt), specifically to accommodate the length of the sequence used for protein purification, whereby the signal peptide was removed and an N-terminal His tag was added via the vector backbone.

[0183] Informal sequence listing

[0184] SEQ ID NO:2

[0185] Description: Flavonifractor proutii GalNAc deacetylase (protein sequence) MRNRRKAVSLLTGLLVTAQLFPTAALAADSSESALNKAPGYQDFPAYYSDSAHADDQVTHPDVVVLEEPWNGYRYWAVYTPNVMRISIYENPSIVASSDGVHWVEPEGLSNPIEPQPPSTRYHNCDADMVYNAEYDAMMAYWNWADDQGGGVGAEVRLRISYDGVHWGVPVTYDEMTRVWSKPTSDAERQVAD GEDDFITAIASPDRYDMLSPTIVYDDFRDVFILWANNTGDVGYQNGQANFVEMRYSDDGITWGEPVRVNGFLGLDENGQQLAPWHQDVQYVPDLKEFVCISQCFAGRNPDGSVLHLTTSKDGVNWEQVGTKPLLSPGPDGSWDDFQIYRSSFYYEPGSSAGDGTMRVWYSALQKDTNNKMVADSSGNLTIQAK SEDDRIWRIGYAENSFVEMMRVLLDDPGYTTPALVSGNSLMLSAETTSLPTGDVMKLETSFAPVDTSDQVVKYTSSDPDVATVDEFGTITGVSVGSARIMAETREGLSDDLEIAVVENPYTLIPQSNMTATATSVYGGTTEGPASNVLDGNVRTIWHTNYAPKDELPQSITVSFDQPYTVGRFVYTPRQNGTN GIISEYELYAIHQDGSKDLVASGSDWALDAKDKTVSFAPVEAVGLELKAIAGAGGFGTAAELNVYAYGPIEPAPVYVPVDDRDASLVFTGAWNSDSNGSFYEGTARYTNEIGASVEFTFVGTAIRWYGQNDVNFGAAEVYVDGVLAGEVNVYGPAAAQQLLFEADGLAYGKHTIRIVCVSPVVDFDYFSYVGE

[0186] SEQ ID NO:4

[0187] Description: Flavonifractor proutii GalNAc deacetylase (removes signal peptide protein sequence) ADSSESALNKAPGYQDFPAYYSDSAHADDQVTHPDVVVLEEPWNGYRYWAVYTPNVMRISIYENPSIVASSDGVHWVEPEGLSNPIEPQPPSTRYHNCDADMVYNAEYDAMMAYWNWADDQGGGVGAEVRLRISYDGVHWGVPVTYDEMTRVWSKPTSDAERQVADGEDDFITAIASPDRYDMLSP TIVYDDFRDVFILWANNTGDVGYQNGQANFVEMRYSDDGITWGEPVRVNGFLGLDENGQQLAPWHQDVQYVPDLKEFVCISQCFAGRNPDGSVLHLTTSKDGVNWEQVGTKPLLSPGPDGSWDDFQIYRSSFYYEPGSSAGDGTMRVWYSALQKDTNNKMVADSSGNLTIQAKSEDDRIWRIGYAE NSFVEMMRVLLDDPGYTTPALVSGNSLMLSAETTSLPTGDVMKLETSFAPVDTSDQVVKYTSSDPDVATVDEFGTITGVSVGSARIMAETREGLSDDLEIAVVENPYTLIPQSNMTATATSVYGGTTEGPASNVLDGNVRTIWHTNYAPKDELPQSITVSFDQPYTVGRFVYTPRQNGTNGIISEY ELYAIHQDGSKDLVASGSDWALDAKDKTVSFAPVEAVGLELKAIAGAGGFGTAAELNVYAYGPIEPAPVYVPVDDRDASLVFTGAWNSDSNGSFYEGTARYTNEIGASVEFTFVGTAIRWYGQNDVNFGAAEVYVDGVLAGEVNVYGPAAAQQLLFEADGLAYGKHTIRIVCVSPVVDFDYFSYVGE

[0188] SEQ ID NO:5

[0189] explanation: His Tag Flavonifractor proutii GalNAc deacetylase (pET16a-protein sequence) M.G. HHHHHHHHHSSGADSSESALNKAPGYQDFPAYYSDSAHADDQVTHPDVVVLEEPWNGYRYWAVYTPNVMRISIYENPSIVASSDGVHWVEPEGLSNPIEPQPPSTRYHNCDADMVYNAEYDAMMAYWNWADDQGGGVGAEVRLRISYDGVHWGVPVTYDEMTRVWSKPTSDAERQVADGEDDFITAIASPDRYDML SPTIVYDDFRDVFILWANNTGDVGYQNGQANFVEMRYSDDGITWGEPVRVNGFLGLDENGQQLAPWHQDVQYVPDLKEFVCISQCFAGRNPDGSVLHLTTSKDGVNWEQVGTKPLLSPGPDGSWDDFQIYRSSFYYEPGSSAGDGTMRVWYSALQKDTNNKMVADSSGNLTIQAKSEDDRIWRIGYA ENSFVEMMRVLLDDPGYTTPALVSGNSLMLSAETTSLPTGDVMKLETSFAPVDTSDQVVKYTSSDPDVATVDEFGTITGVSVGSARIMAETREGLSDDLEIAVVENPYTLIPQSNMTATATSVYGGTTEGPASNVLDGNVRTIWHTNYAPKDELPQSITVSFDQPYTVGRFVYTPRQNGTNGIISEY ELYAIHQDGSKDLVASGSDWALDAKDKTVSFAPVEAVGLELKAIAGAGGFGTAAELNVYAYGPIEPAPVYVPVDDRDASLVFTGAWNSDSNGSFYEGTARYTNEIGASVEFTFVGTAIRWYGQNDVNFGAAEVYVDGVLAGEVNVYGPAAAQQLLFEADGLAYGKHTIRIVCVSPVVDFDYFSYVGE

[0190] SEQ ID NO:7

[0191] Description: Flavonifructor platygalactosaminidase

[0192] SEQ ID NO:9

[0193] Description: Flavonifractor platygalactosaminidase (removal signal peptide protein sequence)

[0194] SEQ ID NO:10

[0195] explanation: His Tag Flavonifractor platygalactosaminidase carrying (pET16a-protein sequence) M.G. HHHHHHHHH

[0196] SEQ ID NO:12

[0197] Description: Clostridium tertium isolated protein sequence 099345757.1-Ct5757 (fusion of galactosaminidase and GalNAc deacetylase linked by CBM (original protein sequence))

[0198] SEQ ID NO:14

[0199] Description: Clostridium tertium 5757 (Ct5757) isolated protein sequence excluding signal peptide (identification number 099345757.1-Ct5757)

[0200] SEQ ID NO:15

[0201] explanation: His Tag and a Clostridium tertium 5757 (Ct5757) fusion protein sequence expression construct (in a pET28a vector) with a thrombin cleavage site MGSS HHHHHH

[0202] SEQ ID NO:17

[0203] explanation: His Tag and Clostridium tertium 5757 (Ct5757) GalNAc deacetylase protein sequence expression construct (in pET28a vector) with a thrombin cleavage site MGSS HHHHHH SSGLVPRGSHSGQYWLVFQPDNDVLQTKTNPSSMKQSANNNPYNYNILPNSFPIGTGYNAYKGDVSFYATFKEASSQAIPQNSWALKYVDSEETTGENGRATNAFDGNNNTIWHTKYSGGNAAPMPHEIQIDLR GVYNINQINYLPRQDGGTNGTIKDYEVYLSLDGVNWGQPISKGTFESNSTEKIVKFNETKSRYVKLKALSEINNKQFTTVADLKVFGWEISKIEKPLQNAETYLNIPTYDGLNQSTHPDVKYFKNGWNGYKYWM IMTPNRTGSSVAENPSILASDDGINWEVPAGVTNPIAPMPQVGHNCDVDMIYNEATDELWVYWVESDDITKGWVKLIKSKDGVNWSSQQVVVDDNRAKYSTLSPSIIFKDNKYYMWSVNTGNSGWNNQSNKVEL RESDGVNWSNPTVVNTLAQDGSQIWHVNVEYIPSKNEYWAIYPAYKNGTGSDKTELYYAKSSDGVNWTTYKNPILSKGTSGKWDDMEIYRSCFVYDEDTNMIKVWYGAVSQNPQIWKIGFTENDYDKFIEGLTQ

[0204] SEQ ID NO:19

[0205] explanation: His Tag and Clostridium tertium 5757 (Ct5757) protein sequence galactosaminidase expression construct with thrombin cleavage site (in pET28a vector) MGSS HHHHHHSSGLVPRGSHYNLIDNISVEKLDTDISQANENVFLNGNGIALEVDNRGATCIYLVDENGVKTKATTSLDTADFSGYPIIGGQKIRDFVIISKNLEENINSILGVGNRLTIISKSSSTNLIRKIVFETSNSNPGAIYSTVSYKAESNDLLVDSFHENEYTMSLGQGPFLAYQGCADQQGANTIVNVTNGYNHNSGQNNYSVGVPFSYVYNSVGGIGIDDASTSRREFKLPIIGKDNTVSLGMEWNGQTLKKGAETAIGTSVITTTNGDYYSGLKSYAEVMKDKGISAPASIPDIAYDSRWESWGFEFDFTIEKIVNKLDELKAMGIKQITLDDGWYTYAGDWKLSPQKFPNGNADMKYLTDEIHKRGMTAILWWRPPVDGGINSKLVSEHPEWFIKNSQGNMVRLPGPGGNGGTAGYALCPNSEGSIQHHKDFVTVALEEWGFDGFKEDYVWGIPKCYDSSHKHSSLSDTLENQYKFYEAIYEQSIAINPDTFIELCN CGTPQDFYSTPYVNHAPTADPISRVQTRTRVKAFKAIFGDDFPVTTDHNSVWLPSALGTGSVMITKHTTLSSDRQYNKYFGLARDLELAKGEFIGNLYKYGIDPLESYVIRKGEDIYYSFYKDNSSYSGNIEIKGLDSNATYRIEDYVNNRVIARGVKGPTATINTSFTDNLLVRAIPDDTPAEVTTFDVGNNTILSSTDSGNSKYLNAVSTTLEKTATIDSLSIYIGNNSENGKLQIAIYDDNNGKPGTKKAYVEEFVPTKNSWNTKKVNSVNTLPSGQYWLVFQPDNDVLQTKTNPSSMKQSANNNPYNYNILPNSFPIGTGYNAYKGDVSFYATFKEASSQAIPQNSWALKYVDSEETTGENGRATNAFDGNNTIWHTKYSGGNAAPMPHEIQIDLRGVYNINQINYLPRQDGGTNGTIKDYEVYLSLDGVNWGQPISKGTFESNSTEKIVKFNETKSRYVKLKALSEINNKQFTTVADLKVFGWEISKIEK

[0206] SEQ ID NO:21

[0207] explanation: His Tag and the Robinsoniella peoriensis Rp1021 galactosaminidase protein expression construct with a thrombin cleavage site (in the pET28a vector) MGSS HHHHHH

[0208] SEQ ID NO:23

[0209] explanation: His Tag and a Ruthenibacterium lactatiformans R18755 GalNAc deacetylase protein sequence expression construct (in a pET28a vector) with a thrombin cleavage site. MGSS HHHHHH SSGLVPRGSHEETDLLVNGGFETGDSTGWNWFNNAVVDSAAPHSGNYCAKVAKNSSYEQVVTVSPDTKYVLTGWAKSEGSSVMTLGVKNYGGQETFSATLSADYQQLAVTFTTG PNAQTATIYGYRQNSGSGAGYFDDVELTAVQDFAPYQPLANAIAPQAIPTYDGANQPTHPSVVKFEQPWNGYLYWMAMTPYPFNDGSYENPSIVASNDGENWIVPEGVSNPLAGT PSPGHNCDVDLVYVPASDELRMYYVEADDIISSRVKMISSRDGVHWSEPQVVMQDLVRKYSILSPSIEILPDGTYMMWYVDTGNAGWNSQNNQVKYRTSADGIKWSGAVTCTDF VQPGYQIWHIDVHYDTSSGAYYAVYPAYPNGTDCDHCNLFFAVNRTGKQWETFSRPILKPSTEGGWDDFCIYRSSMLIDDGMLKVWYGAKKQEDSSWHTGLTMRDFSEFMKILER

[0210] SEQ ID NO:25

[0211] explanation: His Tag and the Robinsoniella peoriensis Rp 3671 GalNAc deacetylase protein expression construct with a thrombin cleavage site (in the pET28a vector) MGSS HHHHHH

[0212] SEQ ID NO:27

[0213] explanation: His Tag and the Robinsoniella peoriensis Rp 3672 GalNAc deacetylase protein expression construct (in pET28a vector) with a thrombin cleavage site. MGSS HHHHHH

[0214] SEQ ID NO:29

[0215] explanation: His Tag and Robinsonia peoriensis Rp 3671 GalNAc deacetylase protein Rp3671 expression construct with thrombin cleavage site (in pET28 a vector) MGSS HHHHHHSSGLVPRGSHSPLSAAAESGTGTRLVKGQTGYLTEEQAIRNQEQTTEEREQKLTGEETAEVLMEGTKDSGIVQTEEVQTKEMQTEDAQTEEVQTEEMQTEDAQTKE VQTEEMQTEDAQTEEVQTKEEPAEETHMKEIQTQGTKKASDRNGKARVTEILEDAQDPANRIVYLSDLQWKSENHTVDSELPTRKDKSFGGGKITLKVDGTVTEFDK GIGTQTDSTIVYDLEGKGYTKFETYVGVDYSQKENIPGEVCDVKFRVKIDDKIVSETGVLDPLSNAVKISVNIPDTAKTLTLYADKVTETWSDHANWADAKFYQALP EPENVAFKKTVVTRKTSDNSEAPVNPDSAVNSSKAVDGVIDSSSYFDFGDQANSGAVRESLYMEVDLKGSYLLSDIQLWRYWKDGRTYAATAIVVAEDENFENAAVI YNSDTTGEIHHLGAGSDMLYAETESGKTFPVPENTKARYIRVYTYGVNGTSGVTNHIVELKVNAYVFGDEILPEKPDDSKIFPNAVNPLKLQGPGTNDQVTHPDVT VFDEPWNGYKYWMAYTPNKPGSSYFENPCIAASNDGVNWEFPAQNPVQPRYDSEIENQNEHNCDTDIVYDPVNDRLIMYWEWAQDEAVNGKTHRSEIRYRVSYDGIN WGVEDKTGVLMTGPTDHGCAIATEGERYSDLSPTVVYDKTEKIYKMWANDAGDVGYENKQNNKVWYRTSQDGISNWSDKTYVENFLGVNEDGLQMYPWHQDIQWVEE FQEYWALQQAFPAGSGPDNSSLRFSKSKDGLHWEPVSEKALITVGAPGTWDAGQIYRSTFWYEPGGAKGNGTFHIWYAALAEGQSHWDIGYTSANYADAMYKLTGSR

[0216] SEQ ID NO:31

[0217] explanation: His Tagand Robinsoniella peoriensis Rp 3672_GalNAc deacetylase_protein expression construct with thrombin cleavage site (in pET28a vector) MGSS HHHHHH

[0218] SEQ ID NO:32

[0219] Description: Clostridium tertium 5757 (Ct5757) GalNAc deacetylase protein sequence HSGQYWLVFQPDNDVLQTKTNPSSMKQSANNNPYNYNILPNSFPIGTGYNAYKGDVSFYATFKEASSQAIPQNSWALKYVDSEETTGENGRATNAFDGNNNTIWHTKYSGGNAAPMPPHEIQIDLRGVYNINQ INYLPRQDGGTNGTIKDYEVYLSLDGVNWGQPISKGTFESNSTEKIVKFNETKSRYVKLKALSEINNKQFTTVADLKVFGWEISKIEKPLQNAETYLNIPTYDGLNQSTHPDVKYFKNGWNGYKYWMIMTPN RTGSSVAENPSILASDDGINWEVPAGVTNPIAPMPQVGHNCDVDMIYNEATDELWVYWVESDDITKGWVKLIKSKDGVNWSSQQVVVDDNRAKYSTLSPSIIFKDNKYYMWSVNTGNSGWNNQSNKVELRES SDGVNWSNPTVVNTLAQDGSQIWHVNVEYIPSKNEYWAIYPAYKNGTGSDKTELYYAKSSDGVNWTTYKNPILSKGTSGKWDDMEIYRSCFVYDEDTNMIKVWYGAVSQNPQIWKIGFTENDYDKFIEGLTQ

[0220] SEQ ID NO:33

[0221] Description: Ruthenibacterium lactatiformans R18755 GalNAc deacetylase protein sequence HEETDLLVNGGFETGDSTGWNWFNNAVVDSAAPHSGNYCAKVAKNSSYEQVVTVSPDTKYVLTGWAKSEGSSVMTLGVKNYGGQETFSATLSADYQQLAVTFTTGPNAQTAT IYGYRQNSGSGAGYFDDVELTAVQDFAPYQPLANAIAPQAIPTYDGANQPTHPSVVKFEQPWNGYLYWMAMTPYPFNDGSYENPSIVASNDGENWIVPEGVSNPLAGTPSPG HNCDVDLVYVPASDELRMYYVEADDIISSRVKMISSRDGVHWSEPQVVMQDLVRKYSILSPSIEILPDGTYMMWYVDTGNAGWNSQNNQVKYRTSADGIKWSGAVTCTDFVQ PGYQIWHIDVHYDTSSGAYYAVYPAYPNGTDCDHCNLFFAVNRTGKQWETFSRPILKPSTEGGWDDFCIYRSSMLIDDGMLKVWYGAKKQEDSSWHTGLTMRDFSEFMKILER

[0222] SEQ ID NO:34

[0223] Description: Robinsonia peoriensis Rp3671 GalNAc deacetylase protein HSPLSAAAESGTGTRLVKGQTGYLTEEQAIRNQEQTTEEREQKLTGEETAEVLMEGTKDSGIVQTEEVQTKEMQTEDAQTEEVQTEEMQTEDAQTKEVQTEEMQT EDAQTEEVQTKEEPAEETHMKEIQTQGTKKASDRNGKARVTEILEDAQDPANRIVYLSDLQWKSENHTVDSELPTRKDKSFGGGKITLKVDGTVTEFDKGIGTQTD STIVYDLEGKGYTKFETYVGVDYSQKENIPGEVCDVKFRVKIDDKIVSETGVLDPLSNAVKISVNIPDTAKTLTLYADKVTETWSDHANWADAKFYQALPEPENV AFKKTVVTRKTSDNSEAPVNPDSAVNSSKAVDGVIDSSSYFDFGDQANSGAVRESLYMEVDLKGSYLLSDIQLWRYWKDGRTYAATAIVVAEDENFENAAVIYNSD TTGEIHHLGAGSDMLYAETESGKTFPVPENTKARYIRVYTYGVNGTSGVTNHIVELKVNAYVFGDEILPEKPDDSKIFPNAVNPLKLQGPGTNDQVTHPDVTVFD EPWNGYKYWMAYTPNKPGSSYFENPCIAASNDGVNWEFPAQNPVQPRYDSEIENQNEHNCDTDIVYDPVNDRLIMYWEWAQDEAVNGKTHRSEIRYRVSYDGINWG VEDKTGVLMTGPTDHGCAIATEGERYSDLSPTVVYDKTEKIYKMWANDAGDVGYENKQNNKVWYRTSQDGISNWSDKTYVENFLGVNEDGLQMYPWHQDIQWVEEF QEYWALQQAFPAGSGPDNSSLRFSKSKDGLHWEPVSEKALITVGAPGTWDAGQIYRSTFWYEPGGAKGNGTFHIWYAALAEGQSHWDIGYTSANYADAMYKLTGSR

[0224] SEQ ID NO:35

[0225] Description: Robinsonia peoriensis Rp3672_GalNAc deacetylase_protein

[0226] SEQ ID NO:36

[0227] Description: Clostridium tertium 5757 (Ct5757) galactosaminidase protein sequence HYNLIDNISVEKLDTDISQANENVFLNGNIALEVDNRGATCIYLVDENGVKTKATTSLDTADFSGYPIIGGQKIRDFVIISKNLEENINSILGVGNRLTIISKSSSTNLIRKIVFETSNSNPGAIYSTVSYKAESNDLLVDSFHENEYTMSLGQGPFLAYQGCADQQGANTIVNVTNGYNHNSGQNNYSVGVPFSYVYNSVGGIGIDDASTSRREFKLPIIGKDNTVSLGMEWNGQTLKKGAETAIGTSVITTTNGDYYSGLKSYAEVMKDKGISAPASIPDIAYDSRWESWGFEFDFTIEKIVNKLDELKAMGIKQITLDDGWYTYAGDWKLSPQKFPNGNADMKYLTDEIHKRGMTAILWWRPPVDGGINSKLVSEHPEWFIKNSQGNMVRLPGPGGNGGTAGYALCPNSEGSIQHHKDFVTVALEEWGFDGFKEDYVWGIPKCYDSSHKHSSLSDTLENQYKFYEAIYEQSIAINPDTFIELCNCGTPQ DFYSTPYVNHAPTADPISRVQTRTRVKAFKAIFGDDFPVTTDHNSVWLPSALGTGSVMITKHTTLSSDRQYNKYFGLARDLELAKGEFIGNLYKYGIDPLESYVIRKGEDIYYSFYKDNSSYSGNIEIKGLDSNATYRIEDYVNNRVIARGVKGPTATINTSFTNLLVRAIPDDTPAEVTTFDVGNNTILSSTDSGNSKYLNAVSTTLEKTATIDSLSIYIGNNSENGKLQIAIYDDNNGKPGTKKAYVEEFVPTKNSWNTKKVNSVNTLPSGQYWLVFQPDNDVLQTKTNPSSMKQSANNNPYNYNILPNSFPIGTGYNAYKGDVSFYATFKEASSQAIPQNSWALKYVDSEETTGENGRATNAFDGNNTIWHTKYSGGNAAPMPHEIQIDLRGVYNINQINYLPRQDGGTNGTIKDYEVYLSLDGVNWGQPISKGTFESNSTEKIVKFNETKSRYVKLKALSEINNKQFTTVADLKVFGWEISKIEK

[0228] SEQ ID NO:37

[0229] Description: Robinsoniaella peoriensis Rp1021 galactosaminidase protein sequence

[0230] <References> Kuznetsova, I.M et al. Int J Mol Sci.(2014) “What Macromolecular Crowding Can Do to a Protein” 15(12):23090 - 23140. Marcus, D,M. et al. Biochem (1964) “Immunochemical Studies on Blood Groups. XXXI. Destruction of Blood Group A Activity by an Enzyme from Clostridium tertium Which Deacetylates N - Acetylgalactosamine in Intact Blood Group Substances” (4)437 - 443. Daniels, G. and Reid M.E. Transfusion (2010) “Blood groups: the past 50 years.” 50(2):281 - 9. doi:10.1111 / j.1537 - 2995.2009.02456.x. Epub 2009 Nov 9 Vox Sang. 2011 Nov;101(4):327 - 32. doi:10.1111 / j.1423 - 0410.2011.01540.x. Epub 2011 Sep 6. Garratty, G. Vox Sang.(2008) “Modulating the red cell membrane to produce universal / stealth donor red cells suitable for transfusion.” 94(2):87 - 95. Epub 2007 Nov 22. Goldstein et al. Science (1982) “Group B erythrocytes enzymatically converted to group O survive normally in A,B,and O individuals.” 215(4529):168-70. US4609627;and CA2272925 Kruskall M.S. et al. Transfusion (2000) “Transfusion to blood group A and O patients of group B RBCs that have been enzymatically converted to group O.” 40(11):1290-8. Clausen, H and Hakomori, S. Vox Sang. (1989) “ABH and related histo-blood group antigens; immunochemical differences in carrier isotypes and their distribution.” 56(1):1-20. EP2243793 Liu, Q.P. et al. J Biol Chem.(2008)“Identification of a GH110 subfamily of alpha 1,3-galactosidases: novel enzymes for removal of the alpha 3Gal xenotransplantation antigen.” 283(13):8545-54. doi:10.1074 / jbc.M709020200. Epub 2008 Jan 28. PCT / US1992 / 010113; and PCT / SE2015 / 050108 US4088538; US4141857; US4206259; US4218363; US4229536; US4239854; US4619897; US4748121; US4749653; US4897352; US4954444; US4978619; US5154808; US5914367; US5962279; US6030933; US6291582; US6254645; US10,016,490; and US10,041,055 Jeong, J.K. et al. J Bacteriol.(2009) “Characterization of the Streptococcus pneumoniae BgaC protein as a novel surface beta-galactosidase with specific hydrolysis activity for the Galbeta1-3GlcNAc moiety of oligosaccharides.” 191(9):3011-23. doi:10.1128 / JB.01601-08. Epub 2009 Mar 6. Singh, A.K. et al. PLoS Pathog.(2014) “Unravelling the multiple functions of the architecturally intricate Streptococcus pneumoniae β-galactosidase, BgaA.” 10(9):e1004364. doi:10.1371 / journal.ppat.1004364. eCollection 2014 Sep. Katayarna, T. et al. J Bacteriol.(2004) “Molecular cloning and characterization of Bifidobacterium bifidum 1,2-alpha-L-fucosidase (AfcA), a novel inverting glycosidase (glycoside hydrolase family 95).” 186(15):4885-93. Williams, S.J. et al. J Biol Chem.(2002) “Aspartate 313 in the Streptomyces plicatus hexosaminidase plays a critical role in substrate-assisted catalysis by orienting the 2-acetamido group and stabilizing the transition state.” 277(42):40055-65. Epub 2002 Aug 8. Bolger, A.M. et al. Bioinformatics.(2014) “Trimmomatic: a flexible trimmer for Illumina sequence data.” 30(15):2114-20. doi: 10.1093 / bioinformatics / btu170. Epub 2014 Apr 1. Li 2013 Treangen, T.J. et al. Curr Protoc Bioinformatics (2011) “Next generation sequence assembly with AMOS.” Chapter 11:Unit 11.8. doi: 10.1002 / 0471250953.bi1108s33. Hyatt, D. et al. BMC Bioinformatics.(2010) “Prodigal: prokaryotic gene recognition and translation initiation site identification.” 11:119. doi:10.1186 / 1471-2105-11-119. Konwar, K.M. et al. Bioinformatics.(2015) “MetaPathways v2.5: quantitative functional, taxonomic and usability improvements.” 31(20):3345-7. doi:10.1093 / bioinformatics / btv361. Epub 2015 Jun 15. Studier, F.W. Protein Expr Purif.(2005) “Protein production by auto-induction in high density shaking cultures.” 41(1):207-34. Palmier M.O. and Van Doren S.R. Anal Biochem. (2007) “Rapid determination of enzyme kinetics from fluorescence: overcoming the inner filter effect.” 371(1):43-51. Epub 2007 Jul 18. Kabsch, W. Acta Crystallogr D Biol Crystallogr.(2010) “XDS” 66(Pt 2):125-32. doi: 10.1107 / S0907444909047337. Epub 2010 Jan 22. Evans, P.R. and Murshudov, G.N. Acta Crystallogr D Biol Crystallogr.(2013) “How good are my data and what is the resolution?” 69(Pt 7):1204-14. doi: 10.1107 / S0907444913000061. Epub 2013 Jun 13. Skubak, P. and Pannu, N.S. Nat Commun.(2013) “Automatic protein structure solution from weak X-ray data.” 4:2777. doi: 10.1038 / ncomms3777. Potterton, L. et al. Acta Crystallogr D Struct Biol.(2018) “CCP4i2: the new graphical user interface to the CCP4 program suite.” 74(Pt 2):68-84. doi: 10.1107 / S2059798317016035. Epub 2018 Feb 1. Emsley, P. and Cowtan, K. Acta Crystallogr D Biol Crystallogr.(2004) “Coot: model-building tools for molecular graphics.” 60(Pt 12 Pt 1):2126-32. Epub 2004 Nov 26. Vagin, A.A. et al. Acta Crystallogr D Biol Crystallogr.(2004) “REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use.” 60(Pt 12 Pt 1):2184-95. Epub 2004 Nov 26. Chen, V.B. et al. Acta Crystallogr D Biol Crystallogr.(2010) “MolProbity: all-atom structure validation for macromolecular crystallography.” 66(Pt 1):12-21. doi: 10.1107 / S0907444909042073. Epub 2009 Dec 21. Zhang 2004 Vocadlo, D.J. et al. Biochemistry.(2002) “A case for reverse protonation: identification of Glu160 as an acid / base catalyst in Thermoanaerobacterium saccharolyticum beta-xylosidase and detailed kinetic analysis of a site-directed mutant.” 41(31):9736-46. Jones, D.R. et al. Biotechnol Biofuels.(2018) “SACCHARIS: an automated pipeline to streamline discovery of carbohydrate active enzyme activities within polyspecific families and de novo sequence datasets.” 11:27. doi: 10.1186 / s13068-018-1027-x. eCollection 2018. Yin, Y. et al. Nucleic Acids Res.(2012) “dbCAN: a web resource for automated carbohydrate-active enzyme annotation.” 40(Web Server issue):W445-51. doi: 10.1093 / nar / gks479. Epub 2012 May 29. Edgar, R.C. Bioinformatics.(2010) “Search and clustering orders of magnitude faster than BLAST.” 26(19):2460-1. doi: 10.1093 / bioinformatics / btq461. Epub 2010 Aug 12. Stamatakis, A. Bioinformatics. (2006) “RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models.” 22:2688-2690. doi:10.1093 / bioinformatics / btl446. Stamatakis, A. and Ott, M. Philos Trans R Soc Lond B Biol Sci. (2008) “Efficient computation of the phylogenetic likelihood function on multi-gene alignments and multi-core architectures.” 363(1512):3977-84. doi: 10.1098 / rstb.2008.0163. Eddy, S.R. Bioinformatics. (1998) “Profile hidden Markov models.” 14(9):755-63. Review. Capella-Gutierrez, S. et al. Bioinformatics. (2009) “trimAl: a tool for automated alignment trimming in large-scale phylogenetic analyses.” 25(15):1972-3. doi: 10.1093 / bioinformatics / btp348. Epub 2009 Jun 8. Matsen, F.A. et al. PLoS One. (2012) “A format for phylogenetic placements.” 7(2):e31009. doi: 10.1371 / journal.pone.0031009. Epub 2012 Feb 22. Letunic, I. and Bork, P. Nucleic Acids Res. (2016) “Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees.” 44(W1):W242-5. doi: 10.1093 / nar / gkw290. Epub 2016 Apr 19. Engler, C. et al. PLoS One. (2008) “A one pot, one step, precision cloning method with high throughput capability.” 3(11):e3647. doi: 10.1371 / journal.pone.0003647. Epub 2008 Nov 5. Kwan, D.H. et al. J Am Chem Soc. (2015) “Toward Efficient Enzymes for the Generation of Universal Blood through Structure-Guided Directed Evolution.” 137(17):5695-705. doi: 10.1021 / ja5116088. Epub 2015 Apr 24. The eleven fosmids were sequenced on an Illumina MiSeq TM and ORFs therein that are present in the CAZy TM database (http: / / www.cazy.org / )(Lombard 2014 Konwar, K.M. et al. Bioinformatics. (2015) “MetaPathways v2.5: quantitative functional, taxonomic and usability improvements.” 31(20):3345-7. doi: 10.1093 / bioinformatics / btv361. Epub 2015 Jun 15. Li, D. et al. Bioinformatics. (2015) “MEGAHIT: an ultra-fast single-node solution for large and complex metagenomics assembly via succinct de Bruijn graph.” 31(10):1674-6. doi: 10.1093 / bioinformatics / btv033. Epub 2015 Jan 20. enzymes from GH4 Add Yip, V.L. and Withers, S.G. J. Amer. Chem. Soc. (2006) “Mechanistic analysis of the unusual redox-elimination sequence employed by Thermotoga maritima BglT: a 6-phospho-beta-glucosidase from glycoside hydrolase family 4.” 126, 8354-8355 Chapanian, R. et al. Nat Commun. (2014) “Enhancement of biological reactions on cell surfaces via macromolecular crowding.” 5:4683. doi: 10.1038 / ncomms5683. Varrot, A. et al. J Mol Biol. (2005) “NAD+ and metal-ion dependent hydrolysis by family 4 glycosidases: structural insight into specificity for phospho-beta-D-glucosides.” 346(2):423-35. Epub 2005 Jan 7. Liu, Q.P. et al. Nat Biotechnol. (2007) “Bacterial glycosidases for the production of universal red blood cells.” 25(4):454-64. Epub 2007 Apr 1. Comfort, D.A. et al. Biochemistry (2007) “Biochemical analysis of Thermotoga maritima GH36 alpha-galactosidase (TmGalA) confirms the mechanistic commonality of clan GH-D glycoside hydrolases.” 46(11):3319-30. Epub 2007 Feb 27. Calcutt, M.J. et al. FEMS Microbiol Lett. (2002) “Identification, molecular cloning and expression of an alpha-N-acetylgalactosaminidase gene from Clostridium perfringens.” 214(1):77-80. Gerbal, A. Maslet, C. and Salmon, C. Vox Sang. (1975) “Immunological aspects of the acquired B antigen.” 28(5):398-403. Judd, W.J. and Annesley, T.M Transfusion medicine reviews (1996) “The acquired-B phenomenon.” 10, 111-117. Kelley, L.A. et al. Nat Protoc. (2015) “The Phyre2 web portal for protein modeling, prediction and analysis.” 10(6):845-58. doi: 10.1038 / nprot.2015.053. Epub 2015 May 7. Ficko-Blean, E. and Boraston, AB. J Biol Chem. (2006) “The interaction of a carbohydrate-binding module from a Clostridium perfringens N-acetyl-beta-hexosaminidase with its carbohydrate receptor.” 281(49):37748-57. Epub 2006 Sep 21. Cohen, M. et al. Blood. (2009) “ABO blood group glycans modulate sialic acid recognition on erythrocytes.” 114(17):3668-76. doi: 10.1182 / blood-2009-06-227041. Epub 2009 Aug 24. Fredslund, F. et al. J Mol Biol. (2011) “Crystal structure of α-galactosidase from Lactobacillus acidophilus NCFM: insight into tetramer formation and substrate binding.” 412(3):466-80. doi: 10.1016 / j.jmb.2011.07.057. Epub 2011 Jul 30.

Claims

1. A composition comprising: (a) a purified GalNAc deacetylase protein; (b) a purified galactosaminidase protein; and A composition comprising:

2. 2. The composition of claim 1, comprising: (a) a purified GalNAc deacetylase protein selected from one or more of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:17, SEQ ID NO:23, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, and SEQ ID NO:35; (b) a purified galactosaminidase protein selected from one or more of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:36, and SEQ ID NO:37; The composition is selected from one or more of the following:

3. 2. The composition of claim 1, comprising a purified enzyme having GalNAc deacetylase activity consisting essentially of an amino acid sequence at least 90% identical to one of SEQ ID NOs: 2, 4, 5, 17, 23, 29, 31, and 32-35, and a purified enzyme having galactosaminidase activity consisting essentially of an amino acid sequence at least 90% identical to one of SEQ ID NOs: 7, 9, 10, 19, 21, 36, and 37.

4. 3. The composition according to claim 1 or 2, comprising: (a) the purified Flavonifractor proutii GalNAc deacetylase proteins of SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:5; (b) the purified galactosaminidase proteins are the purified Flavonifractor platii galactosaminidase proteins of SEQ ID NO: 7, SEQ ID NO: 9 and SEQ ID NO: 10; A composition comprising an enzyme selected from one or more of the following:

5. 3. The composition according to claim 1 or 2, comprising: (a) a purified Clostridium tertium GalNAc deacetylase protein of SEQ ID NO: 17 or SEQ ID NO: 32; (b) a purified galactosaminidase protein, which is a purified Clostridium tertium galactosaminidase protein of SEQ ID NO: 19 or SEQ ID NO: 36; and The composition is selected from one or more of the following:

6. The composition of any one of claims 1 to 5, wherein the GalNAc deacetylase and galactosaminidase are capable of cleaving A antigen at 1 µg / ml or less.

7. The composition of any one of claims 1 to 6, wherein the GalNAc deacetylase and galactosaminidase have A antigen cleavage activity at a pH between about 6.5 and about 7.

5.

8. The composition of any one of claims 1 to 7, wherein the GalNAc deacetylase and galactosaminidase have A antigen cleavage activity at temperatures between 4°C and 37°C.

9. (a) the purified GalNAc deacetylase and the purified galactosaminidase are immobilized; (b) the purified GalNAc deacetylase is immobilized; or (c) the purified galactosaminidase is immobilized; The composition according to any one of claims 1 to 8.

10. 10. The composition of claim 9, wherein the immobilized enzyme is attached to a surface, the surface being selected from one or more of the following: (a) beads or microspheres; (b) a container; (c) tube; (d) a column; or (e) Matrix

11. The composition according to any one of claims 1 to 10, wherein the composition further comprises a crowding agent.

12. 12. The composition of claim 11, wherein the crowding agent is selected from one or more of dextran, dextran sulfate, dextrin, pullulan, poly(ethylene glycol), Ficoll™, and inert proteins.

13. A purified enzyme comprising the Flavonifractor plantii GalNAc deacetylase of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:

5.

14. A purified enzyme comprising the Flavonifractor platii galactosaminidase of SEQ ID NO:7, SEQ ID NO:9 or SEQ ID NO:

10.

15. A purified enzyme comprising the Clostridium tertium GalNAc deacetylase of SEQ ID NO:17 or SEQ ID NO:

32.

16. A purified enzyme comprising the Clostridium tertium galactosaminidase of SEQ ID NO:19 or SEQ ID NO:

36.

17. An isolated nucleic acid sequence encoding a GalNAc deacetylase selected from one or more of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:16, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, and SEQ ID NO:

30.

18. An isolated nucleic acid sequence encoding a galactosaminidase selected from one or more of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:18, and SEQ ID NO:

20.

19. 19. A vector comprising a nucleic acid according to claim 17 or 18 and a heterologous nucleic acid sequence.

20. 20. The vector of claim 19, wherein the heterologous nucleic acid sequence is selected from one or more of a protein tag and a cleavage site.

21. The protein tag may be an albumin binding protein (ABP), alkaline phosphatase (AP), AU1 epitope, AU5 epitope, AviTag, bacteriophage T7 epitope (T7-tag), bacteriophage V5 epitope (V5-tag), biotin-carboxy carrier protein (BCCP), bluetongue virus tag (B-tag), single domain camelid antibody (C-tag), calmodulin binding peptide (CBP or calmodulin-tag), chloramphenicol acetyltransferase (CAT), cellulose binding domain (CBP), chitin binding domain (CBD), choline binding domain (CBD), dihydrofolate reductase (DHFR), DogTag, E2 epitope, E-tag, FLAG epitope (FLAG-tag), galactose binding protein (GBP), green fluorescent protein (GFP), Glu-Glu (EE-tag), glutathione S-transferase (GST), human influenza hemagglutinin (HA), HaloTag™, alternating histidine and glutamine tag (HQ tag), alternating histidine and asparagine tag (HN-tag), histidine affinity tag (HAT), horseradish peroxidase (HRP), HSV epitope, isopep tag (Isopep-tag), ketosteroid isomerase (KSI), KT3 epitope, LacZ, luciferase, maltose binding protein (CBP), Myc epitope (Myc-tag), NE-tag, NusA, PDZ domain, PDZ ligand, polyarginine (Arg-tag), polyaspartic acid (Asp-tag), polycysteine ​​(Cys-tag), polyglutamic acid (Glu-tag), Polyhistidine (His-tag), polyphenylalanine (Phe-tag), Profinity eXact, Protein C, Rho1D4 tag, S1-tag, S-tag, Softag1, Softag3, SnoopTag Jr, SnoopTag, SpotTag, SpyTag (Spy-tag), streptavidin binding peptide (SBP), Staphylococcal protein A (Protein A), Staphylococcal protein G (Protein G), StrepTag, streptavidin (SBP-tag), StrepTag II, Sdy-tag, small ubiquitin-like modifier (SUMO),21. The vector of claim 20, wherein the tag is selected from one or more of the following: tandem affinity purification (TAP), T7 epitope, tetracysteine ​​tag (TC tag), thioredoxin (Trx), TrpE, Ty tag, ubiquitin, universal, V5 tag, VSV-G or VSV-tag, and Xpress tag.

22. A vector comprising the nucleic acid of claim 17 or 18.

23. 1. A method for enzymatic cleavage of A antigen from red blood cells, comprising: (a) mixing a GalNAc deacetylase protein and a galactosaminidase protein with (1) blood containing an A antigen, or (2) A or AB type red blood cells; (b) incubating the enzyme with (1) blood, or (2) type A or type AB red blood cells, for a period of time sufficient for the enzyme to cleave the A antigen from the blood or red blood cells.

24. The method of claim 23, wherein the GalNAc deacetylase is a purified protein selected from one or more of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:17, SEQ ID NO:23, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, and SEQ ID NO:35, and the galactosaminidase is a purified protein selected from one or more of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:36, and SEQ ID NO:

37.

25. 24. The method of claim 23, wherein the composition comprises a purified enzyme having GalNAc deacetylase activity consisting essentially of an amino acid sequence that is at least 90% identical to one of SEQ ID NOs: 2, 4, 5, 17, 23, 29, 31, and 32-35, and a purified enzyme having galactosaminidase activity consisting essentially of an amino acid sequence that is at least 90% identical to one of SEQ ID NOs: 7, 9, 10, 19, 21, 36, and 37.

26. 24. The method of claim 23, wherein the GalNAc deacetylase is a purified Flavonifractor platycii GalNAc deacetylase protein of SEQ ID NO:4 or SEQ ID NO:5, and the galactosaminidase is a purified Flavonifractor platycii galactosaminidase protein of SEQ ID NO:9 or SEQ ID NO:

10.

27. The method of any one of claims 23 to 26, wherein the method further comprises adding a crowding agent.

28. 28. The method of claim 27, wherein the crowding agent is selected from one or more of the following: dextran, dextran sulfate, dextrin, pullulan, poly(ethylene glycol), Ficoll™, hyperbranched glycerol, inert proteins.

29. The method of any one of claims 23 to 28, further comprising washing the blood or red blood cells to remove GalNAc deacetylase, galactosaminidase and crowding agents.

30. The method of any one of claims 23 to 29, wherein the GalNAc deacetylase and galactosaminidase are capable of cleaving A antigen at 1 μg / ml or less.

31. The method of any one of claims 23 to 30, wherein the GalNAc deacetylase and galactosaminidase have A antigen cleavage activity at a pH between about 6.5 and about 7.

5.

32. The method of any one of claims 23 to 31, wherein the GalNAc deacetylase and galactosaminidase have A antigen cleavage activity at a temperature between 4°C and 37°C.

33. (a) a purified GalNAc deacetylase protein, and (b) purified galactosaminidase protein; A blood collection and storage system comprising:

34. (a) the GalNAc deacetylase is a purified protein selected from one or more of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:17, SEQ ID NO:23, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, and SEQ ID NO:35; The system of claim 33, wherein (b) the galactosaminidase is a purified protein selected from one or more of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:36, and SEQ ID NO:

37.

35. 34. The system of claim 33, wherein the composition comprises a purified enzyme having GalNAc deacetylase activity consisting essentially of an amino acid sequence at least 90% identical to one of SEQ ID NOs: 2, 4, 5, 17, 23, 29, 31, and 32-35, and a purified enzyme having galactosaminidase activity consisting essentially of an amino acid sequence at least 90% identical to one of SEQ ID NOs: 7, 9, 10, 19, 21, 36, and 37.

36. 36. The system of claim 33, 34 or 35, further comprising a surface to which an enzyme is immobilized, the surface being selected from one or more of the following: (a) beads or microspheres; (b) a container; (c) tube; (d) a column, or (e) Matrix

37. 1. A blood collection and storage device, comprising: (a) surface; (b) a purified GalNAc deacetylase protein immobilized on the surface; and (c) a purified galactosaminidase protein immobilized on said surface.

38. (a) the GalNAc deacetylase is a purified protein selected from one or more of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:17, SEQ ID NO:23, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, and SEQ ID NO:35; 38. The device of claim 37, wherein (b) the galactosaminidase is a purified protein selected from one or more of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:36, and SEQ ID NO:

37.

39. 38. The apparatus of claim 37, wherein the composition comprises a purified enzyme having GalNAc deacetylase activity consisting essentially of an amino acid sequence that is at least 90% identical to one of SEQ ID NOs: 2, 4, 5, 17, 23, 29, 31, and 32-35, and a purified enzyme having galactosaminidase activity consisting essentially of an amino acid sequence that is at least 90% identical to one of SEQ ID NOs: 7, 9, 10, 19, 21, 36, and 37.

40. 38. The device of claim 37, wherein the surface to which the enzyme is immobilized is selected from one or more of the following: (a) beads or microspheres; (b) a container; (c) Pipe (d) a column, or (e) Matrix

41. 41. The device of claim 40, wherein the container is a bag.

42. The composition of claim 10, wherein the container is a bag.

43. 37. The system of claim 36, wherein the container is a bag.

Citation Information

Cited By

  • ELECTRICAL UNIT

    DE102025137642A1